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ABSTRACT 
Lung cancer is the leading cause of cancer death in the U.S. and worldwide. The 
most frequent type of lung cancer is non-small cell lung cancer (NSCLC). Among the 
three major histological types of NSCLC, adenocarcinoma of the lung (ACL) is the most 
prevalent. NSCLC is mostly diagnosed at advanced stages (stage IIIB 18% of cases, stage 
IV 40% of cases) due to the lack of effective early detection methods. The median 
survival of such patients is only 12.3 months when treated with carboplatinum plus taxol 
and the antiangiogenic agent bevacizumab (Sandler et al., 2006). Thus, the discovery of 
alternative therapeutic strategies is of extreme importance. 
Others and we have previously found that Notch signaling plays a crucial role in 
NSCLC. Inhibition of Notch-1 signaling in NSCLC cells causes cell death specifically 
under hypoxia. Our preliminary results indicate that Notch-1 provides necessary survival 
signals to NSCLC cells by positively regulating insulin-like growth factor-1 receptor 
(IGF-1R) to activate the Akt-1 pathway. This effect is exacerbated by the fact that Notch-
1 represses phosphatase and tensin homolog (PTEN) expression (Eliasz et al., 2010). 
Therefore, the overall hypothesis is that an inhibitor of Notch activation, such as γ-
secretase inhibitor (GSI) MRK-003; or a fully humanized antibody against the human 
IGF-1R that promotes the receptor degradation (IGF-1R inhibitory antibody) MK-0646; 
or a pan-Akt inhibitor MK-2206, alone or in combinations, could improve the efficacy of 
chemotherapy for advanced NSCLC by specifically targeting hypoxic NSCLC tumor 
 xvi 
environment. We tested this hypothesis in mouse preclinical models of orthotopic, 
advanced (metastatic) NSCLC. Our results indicate that all treatments (with the exception 
of MK-2206, which caused lethal glucose intolerance), significantly improved the 
survival of mice compared to controls. The combination therapies of GSI plus cisplatin 
and GSI plus IGF-1R inhibitory antibody significantly improved median survival 
compared to single agents. The expression levels of hypoxic markers were reduced in 
GSI treated mice lungs, indicating that GSI treatment caused specific cell death of 
hypoxic tumor areas. GSI treatment also significantly reduced cancer metastasis to the 
liver and brain. MK-0646 had tumoristatic effect at the beginning of the treatment. 
However, tumor cells resumed growth and eventually led to the death of the experimental 
animals. We found that tumor evasion from MK-0646 treatment was mediated by over-
activated epidermal growth factor receptor (EGF-R) signaling pathway, which is due to 
stabilization of the total EGF-R protein and Akt-1 mediated upregulation of 
Amphiregulin, an EGF-R ligand. Of relevance, the sensitivity of NSCLC cells to erlotinib 
(EGF-R inhibitor) was increased after MK-0646 treatment. Sequential therapy of MK-
0646 followed by erlotinib significantly prolonged survival of the mice compared to each 
single agent or simultaneous administration of two drugs. 
Together, these data indicate the following: Notch inhibition seems to specifically 
target tumor hypoxic regions in vivo and to significantly inhibit tumor metastasis. We 
also found serendipitously that the administration of IGF-1R inhibitory antibody 
sensitizes NSCLC to erlotinib, a second-line therapeutic agent whose sensitivity is 
xvii 
difficult to predict, with the notable exception of NSCLC with activating mutations in the 
EGF-R itself. 
1 
CHAPTER 1 
INTRODUCTION 
LUNG CANCER AND TREATMENT 
Being the second most common type of cancer, lung cancer is the leading cause 
of cancer related deaths in the U.S. and worldwide, in both men and women. Each year, 
the number of people who have died from lung cancer is more than that of colon, breast, 
and prostate cancers combined. For the United States in 2013, it is estimated that there 
will be 228,190 new cases and 159,480 deaths from lung cancer, which will account for 
about 27% of all cancer related deaths (Siegel et al., 2013). Based on major histological 
features, lung cancer is divided into two major types: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). Accounting for about 87.5% of diagnosed lung 
cancer, NSCLC is the most common type of lung cancer. NSCLC is further grossly sub-
characterized into three major histological types: squamous cell carcinoma, large-cell 
carcinoma and adenocarcinoma of the lung. Adenocarcinoma of the lung (ACL) is the 
most common type of NSCLC, which accounts for 40% of all lung cancer cases. It is also 
the most prevalent lung cancer in women and in individuals who have never smoked 
(Shigematsu et al., 2005). It seems to originate at the broncho-alveolar junction of the 
lungs, and often spreads to spaces between the lungs and the chest wall, which makes it 
more difficult to detect at an early stage (Galluzzo and Bocchetta, 2011).  Early stage 
lung cancer often does not cause any symptoms. In most cases, the tumor cells have 
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already spread to other parts of the body before it can be detected with an imaging test 
such as a chest x-ray.  Therefore, most NSCLC cases are diagnosed at advanced disease 
stages. Based on the size of the lung tumor, and whether cancer cells have spread to 
lymph nodes or other tissues, lung cancer can be diagnosed at four different stages (from 
stage I to IV, see Table 1.1 of NSCLC staging with clinical definition). The overall 5-
year survival rate for NSCLC cancer is only 15%. The NSCLC standard treatment 
strategies and survival rates for each stage are summarized in Table 1.2 (Ries, 2007). Due 
to the lack of effective early detection methods, 18% of the NSCLC patients are 
diagnosed at stage IIIB and 40% of patients are diagnosed at stage IV (Wisnivesky et al., 
2005). Stage IIIB and IV are the advanced stages (metastatic) in which cancer has spread 
from the chest to other parts of the body, such as the brain, bones, liver and the other lung 
(Goldstraw et al., 2007). The median survival of such patients is only 12.3 months when 
treated with platinum plus taxol and Avastin (Bevacizumab), a monoclonal antibody 
against vascular endothelial growth factor A (VEGF-A) (Sandler et al., 2006). Moreover, 
recent studies indicated that inhibitors targeting the VEGF pathway might elicit tumor 
adaptation, increasing tumor invasiveness, and hence promote tumor progression to 
higher malignant stages (Paez-Ribes et al., 2009). Therefore, the introduction of effective 
screening methods and finding of alternative therapeutic strategies are of extreme 
importance. 
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Table 1.1 The TNM classification for staging of non-small cell lung cancer 
(NSCLC). The staging system was developed by the American Joint Commission on 
Cancer (Goldstraw et al., 2007). 
 
Stage T (Primary tumor) N (Regional lymph nodes) 
M (Distant 
metastasis) 
IA 
T1a: Tumor ≤ 2 cm in the 
greatest dimension 
N0: No regional node 
metastasis 
M0: No distant 
metastasis 
T1b: Tumor > 2 cm but ≤ 3 
cm in the greatest dimension N0 M0 
IB T2a: Tumor > 3 cm but ≤ 5 cm in the greatest dimension N0 M0 
IIA 
T1a 
N1: Metastasis in 
ipsilateral peribronchial 
and/or ipsilateral hilar 
lymph nodes and 
intrapulmonary nodes, 
including involvement by 
direct extension 
M0 
T1b N1 M0 
T2a N1 M0 
T2b: Tumor > 5 cm but ≤ 7 
cm in the greatest dimension N0 M0 
IIB 
T2b N1 M0 
T3: Tumor > 7 cm or one that 
directly invades any of the 
following: 
• Chest wall, diaphragm, 
phrenic nerve, mediastinal 
pleura, or parietal 
pericardium 
• Tumor in the main 
bronchus < 2 cm distal to 
the carina but without 
involvement of the carina 
• Associated 
atelectasis/obstructive 
pneumonitis of the entire 
lung or separate tumor 
nodule(s) in the same lobe 
N0 M0 
IIIA 
T1: Tumor ≤ 3 cm in greatest 
dimension, surrounded by 
lung or visceral pleura, no 
N2: Metastasis in the 
ipsilateral mediastinal 
and/or subcarinal lymph 
M0 
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bronchoscopic evidence of 
invasion, more proximal than 
the lobar bronchus; 
superficial spreading of tumor 
in the central airways  
node(s) 
T2: Tumor > 3 cm but ≤ 7 cm 
or tumor with any of the 
following: 
• Invades visceral pleura 
• Involves the main 
bronchus ≥ 2 cm distal to 
the carina 
• Associated with 
atelectasis/obstructive 
pneumonitis extending to 
hilar region but not 
involving the entire lung 
N2 M0 
T3 N2 M0 
T3 N1 M0 
T4: Tumor of any size that 
invades any of the following: 
mediastinum, heart, great 
vessels, trachea, recurrent 
laryngeal nerve, esophagus, 
vertebral body, or carina; 
separate tumor nodule(s) in a 
different ipsilateral lobe 
N0 M0 
T4 N1 M0 
IIIB 
T4 N2 M0 
T1 
N3: Metastasis in the 
contralateral mediastinal, 
contralateral hilar, 
ipsilateral or contralateral 
scalene, or 
supraclavicular lymph 
nodes 
M0 
T2 N3 M0 
T3 N3 M0 
T4 N3 M0 
IV T Any N Any 
M1a: Separate 
tumor nodule(s) 
in a contralateral 
lobe; tumor with 
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pleural nodules or 
malignant pleural 
(or pericardial) 
effusion  
T Any N Any M1b: Distant metastasis 
 
 
 
Table 1.2 Standard Treatment Options for NSCLC and 5-year survival rates 
according to stage. The treatment strategies for NSCLC are obtained from the NIH 
website. The 5-year survival rates were calculated from the National Cancer Institute's 
Surveillance, Epidemiology, and End Results (SEER) database, based on people who 
were diagnosed with non-small cell lung cancer between 1998 and 2000 (Ries, 2007). 
 
Stage Standard Treatment Options Survival Rate (5Y) 
IA and IB Surgery  Radiation therapy 
IA: 49% 
IB: 45% 
IIA and IIB 
Surgery 
Chemotherapy followed by surgery 
Surgery followed by chemotherapy 
External radiation therapy 
IIA: 30% 
IIB: 31% 
III
A 
Resectable 
disease 
Surgery followed by chemotherapy 
Chemotherapy followed by surgery 
Surgery followed by chemotherapy combined with 
radiation therapy 
Surgery followed by radiation therapy 
14% 
Unresectable 
disease 
Chemotherapy and radiation therapy 
External radiation therapy alone 
Internal radiation therapy or laser surgery 
Superior 
sulcus tumors 
Radiation therapy alone 
Radiation therapy followed by surgery 
Chemotherapy and radiation followed by surgery 
Surgery alone 
Tumors that 
invade the 
chest wall 
Surgery 
Surgery and radiation therapy 
Radiation therapy alone 
Chemotherapy combined with radiation therapy 
and/or surgery 
IIIB 
Chemotherapy followed by external radiation 
therapy. 
Chemotherapy and radiation therapy Chemotherapy 
5% 
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followed by surgery 
External radiation therapy alone 
External or internal radiation therapy 
IV 
Combination chemotherapy 
Maintenance therapy with an anticancer drug after 
combination chemotherapy 
Combination chemotherapy and targeted therapy 
with a monoclonal antibody 
Targeted therapy with a tyrosine kinase inhibitor 
External radiation therapy 
Laser therapy and/or internal radiation therapy 
1% 
 
 
 
HYPOXIC TUMOR MICROENVIRONMENT 
Hypoxia-induced signaling 
Hypoxia-induced signaling is primarily mediated by hypoxia-inducible factors 
(HIFs), including HIF-1 and HIF-2 (Bruick, 2003; Semenza, 1999). HIF is a heterodimer 
containing a constitutively expressed HIF-β subunit (also known as ARNT, the aryl 
hydrocarbon receptor nuclear translocator) and HIF-α subunit, which is regulated and 
stabilized by low level of oxygen (Wang and Semenza, 1995). When HIF-α is stabilized, 
it subsequently dimerizes with the β subunit, and the heterodimer functions as a 
transcription factor that binds to the specific hypoxia response elements (HREs) on the 
promoters of its target genes, mediating the transcription of hypoxia responsive targets. 
The regulation of HIF-1α expression by oxygen is at the level of protein degradation. 
HIF-1α can be recognized by E3 ubiquitin ligase Von Hippel-Lindau (VHL) tumor-
suppressor protein and targeted for proteasomal degradation only when proline residues 
402 and 564 are hydroxylated (Ivan et al., 2001). The hydroxylation reaction requires the 
presence of oxygen, and is catalyzed by the PHD 1-3 enzymes (prolyl hydroxylase-
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domain protein 1-3) (Bruick and McKnight, 2001). In addition to HIF-1α stabilization, 
the level of oxygen also regulates the interaction between HIF-1α and its transcriptional 
coactivators P300 and CBP. In the presence of oxygen, FIH-1 (factor inhibiting HIF-1) 
mediated hydroxylation of asparagine residue 803 of HIF-1α blocks the binding between 
HIF-1α and P300/CBP, therefore inhibiting the transcription of HIF-1α downstream 
target genes (Lando et al., 2002; Mahon et al., 2001). Similar to HIF-1α, the protein level 
of HIF-2α and its transcriptional activity are also regulated by hydroxylation of proline 
and asparagine residues. The regulation of HIF-1α and HIF-2α by the level of oxygen is 
universal to almost all types of mammalian cells. Both HIF-α and HIF-β have been 
linked with the molecular mechanisms that regulate carbohydrate and lipid metabolism 
(Pescador et al., 2010), erythropoiesis and iron metabolism (Haase, 2010), and 
angiogenesis (Pugh and Ratcliffe, 2003). Furthermore, HIF-1 and HIF-2 are also 
important in regulating embryonic stem cells in early embryo development, which is a 
naturally occurring hypoxic environment due to the lack of fully established vasculature 
(Simon and Keith, 2008). Due to a complete lack of cephalic vascularization, HIF-1α 
knockout mice are embryonic lethal (Ryan et al., 1998).  
 
Hypoxia and cancer 
In solid tumors, there are always regions with low levels of oxygen, creating a 
hypoxic tumor microenvironment. This is due to the fact that tumor cells proliferate 
quickly and the vasculature is not completely established. Hypoxia is often associated 
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with malignant progression and poor clinical outcomes in advanced cancers (Brizel et al., 
1999; Brizel et al., 1996; Hockel et al., 1996; Nordsmark and Overgaard, 2004). This is at 
least partially due to the low level of oxygen counteracting the effects of chemotherapy 
and radiation therapy, which kill tumor cells by targeting highly proliferating cells and 
generating reactive oxygen species, respectively (Brown, 2007).  
Hypoxia induces a wide range of biological changes that contribute to the 
progression of malignant tumor cells. It has been shown that hypoxia is associated with 
activation of a number of genes that promote cell proliferation, survival, motility, cell 
adhesion and angiogenesis (Harris, 2002). Hypoxia has been implicated in enhancing 
genomic instability, which contributes to tumorigenesis and malignant progression, 
owing to diminished DNA repair, elevated mutagenesis and genomic rearrangements. 
HIF-1α is able to interfere with the DNA repair mechanism by downregulating 
MutSalpha expression, which recognizes base mismatches (Koshiji et al., 2005). 
Moreover, the expression of DNA mismatch repair (MMR) gene Mlh1 is specifically 
reduced in cells under hypoxia due to histone deacetylation (Mihaylova et al., 2003). 
Furthermore, hypoxia leads to genome rearrangements and mutagenesis due to the 
induction of chromosome fragile sites (Coquelle et al., 1998; Yuan et al., 2000). The 
induction of the expression level of drug resistant genes, such as multidrug resistance 
transporter P-glycoprotein (P-gp) by HIF-1α can ultimately lead to tumor resistance to 
chemotherapeutics (Comerford et al., 2002; Wartenberg et al., 2003).  More importantly, 
recent studies reported that hypoxia also plays an important role in expending or 
maintaining cancer stem cell or the tumor initiating cell population eventually leading to 
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tumor progression (Keith and Simon, 2007). Hypoxia, through the mediation of HIF-1α 
or HIF-2α, was shown to induce the expression of genes that regulate the differentiation 
and homing of stem or progenitor cells, including Notch (Gustafsson et al., 2005; Yuan et 
al., 2000), beta-catenin (Kaidi et al., 2007), Oct-4 (Covello et al., 2006) and c-Myc 
(Gordan et al., 2007). The Notch intracellular domain (NICD) has been shown to 
physically interact with and stabilized by HIF-1α under hypoxia, hence activating the 
downstream signaling that is critical in maintaining an undifferentiated cell status 
(Gustafsson et al., 2005). Additionally, HIF-1α also regulates the expression of the γ-
secretase component APH-1A, suggesting another mechanism that leads to the enhanced 
Notch activity (Wang et al., 2006). In addition to the direct impact of hypoxia on stem 
and progenitor cells, hypoxia also influences the function of stem cell niches. It has been 
shown that hypoxia decreases the potential of mesenchymal progenitor cells to undergo 
myogenic differentiation and maintains the undifferentiated state of niche stromal cells 
(Lin and Yun, 2010). Furthermore, hypoxia promotes epithelial to mesenchymal 
transition (EMT), either by enhancing the production of transforming growth factor β 
(TGFβ) (Nishi et al., 2004; Orphanides et al., 1997) or increasing the activity of the 
Notch intracellular domain (Chen et al., 2007; Gustafsson et al., 2005). Both TGF 
(Miettinen et al., 1994) and Notch (Zavadil et al., 2004) are known regulators that induce 
EMT. EMT is a process through which epithelial cells lose their phenotype and transit to 
a mesenchymal phenotype, considered as a crucial event that promotes cancer 
progression and metastasis. Although HIF-1α and HIF-2α are major regulators that 
mediate chronic cellular responses to hypoxia, there are also HIF-independent pathways 
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contributing to acute hypoxic responses. For examples, hypoxia induced expression of 
the protein “regulated in development and DNA damage responses 1” (REDD-1) 
suppresses the mammalian target of rapamycin kinase complex 1 (mTORC-1), which 
contributes both to normal cellular homeostasis and tumor suppression (DeYoung et al., 
2008). However, in many cases, tumor cells can evade this metabolic checkpoint due to 
inactivation of the REDD-1 pathway, ultimately leading to tumor development and 
progression (Kucejova et al., 2011; Schwarzer et al., 2005). All of the above evidence 
suggests that hypoxia is a critical regulator in enhancing tumorigenesis, increasing tumor 
metastasis and facilitating cancer progression, resulting in an aggressive tumor 
phenotype. Additionally, hypoxia promotes tumor cell resistance to conventional 
chemo/radiotherapy. Therefore, it is of extreme importance to identify novel therapeutic 
strategies to target hypoxic tumor regions for cancer treatment.  
 
THE NOTCH SIGNALING PATHWAY 
The Notch signaling cascade 
The Notch signaling pathway is an evolutionarily conserved signaling pathway, 
which plays an important role during embryonic development and cell differentiation 
(Artavanis-Tsakonas et al., 1999). The mammalian Notch family consists of four 
(Notch1-4) type I transmembrane receptors and five Notch ligands, Jagged-1 (JAG-1), 
JAG-2, Delta-like-1 (DLL-1), DLL-3 and DLL-4 (Lai, 2004). Notch receptors are 
produced as precursor forms. In order to form the active Notch, Notch precursors must 
undergo three sequential proteolytic cleavages (Figure 1.1). The first cleavage is 
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mediated by furin-like convertase in the Golgi (S1 cleavage), which cleaves Notch 
precursor protein to generate the mature form of Notch before its transport to the cell 
surface (Logeat et al., 1998). After the furin-like convertase mediated cleavage (S1 
cleavage), the extracellular and intracellular domains are no longer covalently linked. 
Notch signaling is a cell-cell communication process, which allows the crosstalk between 
the receptor expressing and ligand expressing cells. Since both Notch receptors and 
ligands are transmembrane proteins, cell-cell contact becomes a prerequisite to trigger 
downstream signaling events. Upon the binding of Notch ligand that is expressed on one 
cell to the extracellular domain of the mature Notch receptor on another cell, the ligand is 
trans-endocytosed into the ligand-expressing cell (Parks et al., 2000). This event exposes 
the extracellular cleavage site of Notch to the metalloproteinases ADAM10  (A 
Disintegrin and metalloproteinase domain-containing protein 10) or tumor necrosis 
factor-α-converting enzyme (TACE; also know as ADAM17) (Brou et al., 2000). 
ADAM17/TACE cleaves Notch in vitro, but only the ADAM10 KO mice show the Notch 
deficiency phenotype (Hartmann et al., 2002; Zhao et al., 2001). Hence, probably both 
ADAMs cleave Notch in vivo. This second cleavage mediated by ADAM10 (or 
ADAM17) (S2 cleavage) exposes the binding sites of the transmembrane region of Notch 
to the γ-secretase complex. γ-secretase is a protease complex that contains presenilin 
1(PSEN1), PSEN2, nicastrin (NCSTN), presenilin enhancer 2 (PEN2) and anterior 
pharynx-defective 1 (APH1) proteins (Kaether et al., 2006). The cleavage mediated by γ-
secretase complex (S3 cleavage) results in the release of the Notch intracellular domain 
(NICD), also called activated Notch, to the cytosol and subsequent translocation into the 
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nucleus (Schroeter et al., 1998). There are small molecule compounds that inhibit the γ-
secretase complex mediated cleavage, called γ-secretase inhibitors (GSI). Once activated, 
Notch intracellular domain (NICD) translocates into the nucleus, and binds to C-promoter 
binding factor 1 (CBF-1) (Tamura et al., 1995), resulting in the replacement of the co-
repressors that were bound to CBF-1 with the co-activator protein mastermind-like 1 
(MAML1) and other transcription factors (Oswald et al., 2001). This eventually converts 
the transcriptional repressor complex into a transcriptional activator complex (Jeffries et 
al., 2002; Wu et al., 2000). This transcriptional activator complex then promotes the 
transcription of many downstream target genes, such as HES (the transcriptional 
repressors of the hairy enhancer of split), HEY (the hairy-related transcription factor, 
HRT, also known as HEY) (Iso et al., 2003), p21/Waf1 (Rangarajan et al., 2001), NFkB 
(Oswald et al., 1998), cyclin D1 (Ronchini and Capobianco, 2001) and c-MYC (Klinakis 
et al., 2006).  
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Figure 1.1 The Notch signaling pathway. Notch receptors are produced as precursor 
forms. In order to form the active Notch, Notch precursors must undergo three sequential 
proteolytic cleavages: S1 cleavage is mediated by furin-like convertase in the Golgi, 
which cleaves Notch precursor protein to generate the mature form of Notch before its 
transport to the cell surface; S2 cleavage mediated by ADAM10 (or ADAM17) exposes 
the binding sites of the transmembrane region of Notch to the γ-secretase complex; S3 
cleavage mediated by γ-secretase complex results in the release of the Notch intracellular 
domain (NICD) to the cytosol and subsequent translocation into the nucleus. Once NICD 
translocates into the nucleus, it binds to CBF-1, converting the transcriptional repressor 
complex into a transcriptional activator complex, which promotes the transcription of 
many downstream Notch target genes. 
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Regulation of Notch by hypoxia 
Accumulating evidence has suggested that Notch signaling is activated by 
hypoxia. In primary neural stem cells and colorectal cancer-derived cell lines, hypoxia 
prevents cell differentiation and maintains a stem-like cell phenotype in a Notch 
dependent manner (Gustafsson et al., 2005; Yeung et al.). Using neurogenic rat 
embryonic carcinoma cells, the authors were able to demonstrate that in hypoxia, the 
Notch intracellular domain (NICD) interacts with, and is stabilized by HIF-1α, and the 
complex is recruited to the Notch responsive promoters bound to CBF-1 to activate the 
Notch downstream target genes Hes-1 and Hey-2 (Gustafsson et al., 2005). Additionally, 
Notch signaling has been shown to be required for the hypoxia mediated epithelial-
mesenchymal transition (EMT), as well as for tumor cell migration and invasion 
(Sahlgren et al., 2008). Moreover, hypoxia stimulates pulmonary arterial hypertension by 
activating the NOTCH3-HES-5 signaling pathway (Li et al., 2009). Recently, Lanner and 
colleagues reported that hypoxia upregulated the expression of the Notch ligand DLL-4 
and increased Notch signaling, which promoted arterial differentiation. Since Notch 
signaling also upregulates DLL-4 expression, a positive feedback loop is formed to 
sustain DLL-4 expression and Notch signaling (Lanner et al., 2013).  
  
The role of the Notch pathway in lung cancer 
The important role of the Notch signaling pathway has been implicated in cancer 
development. In many different solid tumors, aberrant activation of Notch signaling can 
lead to tumor cell proliferation and tumorigenesis, such as in breast (Klinakis et al., 
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2006), colorectal (van Es et al., 2005), and pancreatic (Miyamoto et al., 2003) cancers. In 
contrast, Notch signaling seems to have a tumor suppressor role in keratinocytes 
(Rangarajan et al., 2001). Many studies suggest that Notch drives transformation and 
tumor progression mostly by promoting cell proliferation and inhibiting apoptosis. It has 
been shown that inhibition of Notch-3 reduced tumor cell proliferation and caused 
apoptosis of lung cancer cell lines in vitro (Konishi et al., 2007). We have found that 
Notch-1 signaling plays a crucial role in mediating the survival of NSCLC under hypoxia 
(Chen et al., 2007). In addition, another study also indicates that Notch-1 signaling might 
play an important role in the carcinogenesis and progression of NSCLC, since the protein 
levels of Notch-1, Jagged-1 and VEGF were closely correlated with the pathological type 
and lymph node metastasis (Jiang et al., 2007). Furthermore, we have shown that 
inhibition of Notch-1 signaling (either through genetic siRNA downregulation of Notch-1 
or using GSI) in NSCLC cells caused cell death specifically under hypoxia condition. 
This specific effect could be rescued by overexpressing intracellular Notch-1 (NICD). 
Further immunofluorescent staining analysis of intracellular Notch-1 and the hypoxic 
marker Glucose transporter-1 (GLUT-1) indicated that the activated Notch-1 is only 
present in hypoxic areas. Furthermore, we found that the activated Notch-1 under 
hypoxic areas can promote tumor growth through two mechanisms – upregulating IGF-1 
and its receptor IGF-1R and downregulating the expression of phosphatase and tensing 
homolog (PTEN) (Eliasz et al., 2010). Therefore, using small molecule inhibitors, such as 
GSI, to target Notch-1 signaling could be a potential therapeutic strategy to treat NSCLC.  
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THE IGF-1R SIGNALING PATHWAY 
Ligand and receptor signaling 
Insulin-like growth factor 1 receptor (IGF-1R) is a member of receptor tyrosine 
kinase family proteins, which has 70% amino acid homology to the insulin receptor (IR) 
(Ullrich et al., 1986). IGF-1R is ubiquitously expressed. There is one single copy of the 
IGF-1R gene, which is located on chromosome 15. The mRNA of IGF-1R is transcribed 
as a single peptide and then cleaved into two subunits: the α subunit and the β subunit. 
The α subunit is completely extracellular, while the β subunit consists of extracellular, 
transmembrane and intracellular domains. The intracellular domain of the β subunit 
contains the kinase activity. Both the α subunit and β subunit are glycosylated, and they 
can associate with each other to form a monomer through disulfide bonds. Two IGF-1R 
monomers can associate and form an IGF-1R homodimer, which includes two α and two 
β subunits(Ward and Garrett, 2004). The homodimer can be bound by IGF-1R ligands, 
including IGF-1, IGF-2 and insulin. IGF-1 and IGF-2 bind to IGF-1R with high affinity, 
while insulin can also bind to IGF-1R but with 100-1,000 fold lower affinity (Singh and 
Rubin, 1993). IGF-1 and IGF-2 are mostly produced in the liver and secreted to the blood 
stream, but other tissues can also produce IGFs, including the lungs. The local 
bioavailability of IGFs in the peripheral tissues is regulated by IGF binding proteins 
(IGFBPs 1-6). These proteins have opposite functions in regulating IGF-1R signaling. 
They can either have an inhibitory function by trapping IGF-1 and IGF-2 in the 
circulation, preventing them from binding to their receptors, or they can promote IGF-1R 
signaling by prolonging the half-life of IGF-1 and IGF-2 (Pollak et al., 2004). IGF-2 also 
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binds to IGF-2R, which does not have intracellular kinase activity and does not promote 
signaling. However, IGF-2R is able to bind to IGF-1R and inhibit its downstream 
signaling, therefore acting as a negative regulator of the IGF-1R signaling pathway (Yee, 
2006). Due to IGF-1R and insulin receptor (IR) sharing a lot of homology, heterodimers 
containing half IGF-1R monomer and half IR monomer can also be found (Pandini et al., 
1999).  
Upon ligand binding to the IGF-1R receptor, autophosphorylation of the receptor 
occurs, leading to the activation of downstream signaling components (Figure 1.2). There 
are two major downstream signaling pathways of IGF-1R signaling: one involves PI3K, 
AKT and mTOR activation whereas the other is mediated by RAS and MAPK (Tao et al., 
2007). The kinase activity of the receptors leads to phosphorylation of the insulin 
receptor substrate (IRS) family of proteins, which in turn activate PI3K-AKT and several 
other downstream signaling pathways. The consequences of this pathway activation are 
inhibition of apoptosis, cell survival and cell growth (Testa and Tsichlis, 2005). The 
second downstream signaling mediated by RAS and MAPK is triggered by binding of 
Shc to the IGF-1R β subunit, which in turn recruits Grb2 and SOS, resulting in the 
activation of the Ras-Raf1-MEK-ERK signaling pathway. Another mechanism that leads 
to RAS-MAPK activation by IGF-1R is mediated by phosphorylated IRS, which can also 
provide docking sites for Grb2 (Ward et al., 1996). The consequences of ERK signaling 
activation include the stimulation of proliferation, increased motility and survival (Howe 
et al., 2002). 
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Figure 1.2 The IGF-1R signaling pathway. Upon ligand binding to the IGF-1R 
receptor, autophosphorylation of the receptor occurs, leading to the activation of two 
major downstream signaling pathways: one involves activation of PI3K, AKT and mTOR 
signaling whereas the other is mediated by RAS and MAPK. The consequences of 
activation of both of these signaling pathways include increased protein synthesis, cell 
survival and proliferation, and decreased apoptosis. 
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The role of the IGF-1R pathway in NSCLC and other tumors 
The expression of IGF-1R is ubiquitous. Almost all tissues express certain 
amounts of IGF-1R (Abbott et al., 1992). In many types of cancer, including 
osteosarcoma (Burrow et al., 1998), colorectal (Hakam et al., 1999), breast (Happerfield 
et al., 1997; Railo et al., 1994), prostate (Hellawell et al., 2002), lung (Kaiser et al., 
1993), and gastric cancer (Pavelic et al., 2003), IGF-1R has been found to be 
overexpressed, but mutations and gene amplifications of IGF-1R are rarely identified. 
IGF-1R signaling has been linked to tumorigenesis and cancer progression. 
Overexpression of wild type IGF-1R is sufficient to transform both human NIH-3T3 
fibroblast cells and mouse embryo fibroblasts in vitro. In addition, it is been shown that 
mouse fibroblasts that do not have functional IGF-1R are much more difficult to be 
transformed with different viral and cellular oncogenes, such as simian virus (SV) 40 
large T antigen (Sell et al., 1993), Ras (Sell et al., 1994), c-src527 (mutation at tyrosine 
527 to phenylalanine) (Valentinis et al., 1997) and ETV6-NTRK3 (Morrison et al., 2002). 
In addition, in a transgenic mouse model, overexpressing IGF-1 in the basal layer of the 
skin epidermis increased the incidence of squamous papilloma formation. There are also 
studies suggesting that activation of the IGF-1R signaling pathway leads to increased 
tumor cell proliferation and an increased incidence of cancer metastasis. In a mouse 
model of colon cancer, treatment with recombinant IGF-1 significantly increased the 
rates of tumor progression and liver metastasis. Clinical reports also suggested that there 
is a correlation between high level of serum IGF-1 and increased risk of developing 
different types of cancer, including prostate, breast, colorectal, ovarian, bladder and lung 
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cancer in humans. Besides the role of tumorigenesis and metastasis, IGF-1R also has a 
significant anti-apoptotic signaling capacity. Overexpression of IGF-1R has been shown 
to protect fibroblasts from UV-B light induced apoptosis (Kulik et al., 1997). Activation 
of the IGF-1R signaling pathway has also been shown to have an inhibitory role in 
chemical (D'Ambrosio et al., 1997) or cytokine (Wu et al., 1996) induced apoptosis. In 
addition, Trastuzumab (Herceptin), a HER2/neu receptor inhibitory antibody, can only 
inhibit breast cancer cell proliferation when the level of IGF-1 is minimal (Lu et al., 
2001), suggesting activation of IGF-1R signaling can rescue cells from Trastuzumab (a 
monoclonal antibody that interferes with the HER2/neu receptor) mediated apoptosis. 
Many studies have shown that IGF-1, IGF-2 and IGF-1R are expressed in NSCLC 
cell lines, as well as human lung tumor tissues of different histological sub-types (Jaques 
et al., 1988; Kaiser et al., 1993; Minuto et al., 1986; Nakanishi et al., 1988; Rotsch et al., 
1992). Moreover, IGF-1 and -2 treatments of human small cell and non-small cell lung 
cancer cell lines promote cell growth and proliferation (Favoni et al., 1994). To study the 
role of IGF-1 and IGF-2 on tumor formation in the lung, an IGF-1 transgenic mouse 
model, where IGF-1 is specifically overexpressed in the alveolar epithelial cells, was 
generated. Compared to their nontransgenic littermates, these mice are more prone to 
have adenomatous hyperplasia (the over-growth of the endometrium) and to form 
spontaneous pulmonary adenomas in older mice (>1yr) (Frankel et al., 2005). In addition, 
overexpression of IGF-2 in the lung epithelium significantly increased the incidence of 
developing lung tumors, especially in mice order than 18 months (Moorehead et al., 
2003). Several studies have suggested that high plasma levels of IGF-I and low levels of 
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IGFBP-3 were associated with an increased risk of lung cancer (Renehan et al., 2004; 
Spitz et al., 2002; Yu et al., 1999). In lung cancer as well as other solid tumors, the 
crosstalk between IGF-1R and epidermal growth factor (EGF) receptor (EGF-R) has been 
suggested. IGF-1R/EGF-R heterodimerization has been found in erlotinib treated NSCLC 
cells, leading to the activation of the IGF-1R downstream signaling components 
PI3K/Akt and MAPK, which provides survival signals to the cells (Morgillo et al., 2006). 
Besides IGF-1R/EGF-R herterodimerization, another possible mechanism that leads to 
interaction between these two receptors is through activating G-protein coupled receptors 
(GPCRs). It has been shown that activation of IGF-1R turns on many GPCRs (Delcourt 
et al., 2007). On the other hand, activation of GPCRs can induce metalloprotease 
(ADAM) protein family mediated shedding of EGF-R ligands (Sahin et al., 2004) and 
lead to receptor activation. Additionally, in a tamoxifen-resistant breast cancer cell line, 
an EGF-R tyrosine kinase inhibitor (TKI) can disrupt the interaction between EGF-R and 
IRS-1 and promote association of IGF-1R and IRS-1, thus promoting IGF-1R signaling 
(Knowlden et al., 2008). Our study on IGF-1R resistance in NSCLC, on the other hand, 
showed that IGF-1R inhibition could activate EGF-R signaling and promote tumor 
growth, suggesting another mechanism of IGF-1R/EGF-R signaling crosstalk. 
 
IGF-1R as a target for cancer treatment 
Since IGF-1R plays an important role in tumorigenesis and cancer progression, it 
is generally accepted that IGF-1R could be a potential therapeutic target for cancer 
therapy. In 1989, Arteaga. et al reported that inhibition of IGF-1R using an antibody 
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showed a slower growth of tumors in a mouse xenograft breast cancer model. This is the 
first study suggesting that an antibody against IGF-1R could be used to treat cancer. 
Since then, there has been more and more evidence indicating that the IGF-1R signaling 
pathway could be used as a therapeutic target for cancer therapy. The finding that mouse 
embryos carrying null mutations of the gene encoding Igf-1r display growth deficiency 
(45% normal size) (Liu et al., 1993) suggests that IGF-1R is not 100% required for 
normal embryo growth and that there are other pathways that could contribute to the 
growth. Moreover, the effect of IGF-1R on cell growth has been evaluated in anchorage 
independent conditions. The growth of human melanoma cells is strongly inhibited when 
an antisense RNA against IGF-1R RNA is introduced into nude mice, while there is no 
effect when the same antisense RNA is introduced into the same cells grown in 
monolayers (Resnicoff et al., 1994).  Since IGF-1R is important for mediating viral and 
cellular oncogene transformation, it is reasonable to hypothesize that downregulation or 
inhibition of the IGF-1R signaling pathway may play a role in suppressing tumor growth. 
Surprisingly, downregulation of IGF-1R not only inhibited tumor growth, but also caused 
apoptosis especially in anchorage independent conditions. Therefore, IGF-1R signaling 
has been used as a well-studied therapeutic target in cancer treatment. Currently there are 
three different groups of strategies to target IGF-1R signaling: anti-receptor antibodies, 
anti-ligand neutralizing antibodies and small molecule tyrosine kinase inhibitors. Many 
studies have used a number of different IGF-1R specific inhibitory antibodies to inhibit 
tumor xenografts in mice with promising results. So far, many of these antibodies are 
under phase I and II clinical trials (Gualberto and Pollak, 2009). While the results of 
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phase I and II clinical trials indicated low toxicity of these antibodies (mainly 
hyperglycemia and increase insulin levels), a recent phase III trial of figitumumab (a 
human monoclonal antibody against IGF-1R) in NSCLC suggested a lack of efficacy. 
This might be due to the increased resistance since we have found that tumor cells 
became resistant to IGF-1R inhibitory antibody treatments (MK-0646) owing to 
increased EGF-R activity (Liang et al., 2012). Furthermore, other mechanisms to evade 
IGF-1R inhibition have been suggested in different types of cancer. For instance, in 
rhabdomyosarcoma (an aggressive muscle cancer of children and young adults), IGF-1R 
inhibition is associated with HER2 overexpression and MAPK reactivation (Abraham et 
al.). Therefore, the above evidence strongly indicates that the IGF-1R inhibitory antibody 
treatments should be used in combinational or sequential therapies or certain patients 
with predictive biomarkers.  
 
THE EGF-R SIGNALING PATHWAY 
An overview of the EGF-R pathway 
Epidermal growth factor receptor (EGF-R) can be found in many types of cells 
throughout the body and plays an important role in cell growth and cell survival. EGF-R 
is a transmembrane glycoprotein, containing an extracellular ligand binding domain, a 
transmembrane domain, and an intracellular tyrosine kinase domain. EGF-R belongs to 
the ErbB family of receptor tyrosine kinases (RTKs), which includes EGF-R, ErbB-2 
(HER-2), ErbB-3, and ErbB-4 (Walker, 1998). ErbB-2 (HER-2) is highly homologous to 
EGF-R. However, there is no known high affinity ligand of ErbB-2, and it is in a 
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constitutively active conformation (Burgess et al., 2003). ErbB-3 and ErbB-4 are 
structurally related proteins. ErbB-3 does not have tyrosine kinase activity and it can only 
be activated by heterodimerizing with other ErbB family members. EGF-R can be 
activated by certain ligands such as epidermal growth factor (EGF). Upon ligand binding 
to the extracellular domain of EGF-R, the receptor either undergoes homo- or hetero-
dimerization (with other ErbB family proteins) and allows autophosphorylation of the 
tyrosine residues (Olayioye et al., 2000). Phosphorylated tyrosine residues on the 
receptors then serve as docking sites for various adaptor proteins and enzymes, which 
will initiate a number of downstream signaling cascades via recruiting the adaptors 
growth factor receptor-bound protein 2 (GRB2) and the SH2 domain-containing family 
of proteins. The main signaling cascades include the Ras-Erk1/2 pathway, the 
phosphotidylinositol-3 kinase (PI3K)-Akt pathway, the phospholipase Cγ-protein kinase 
C pathway and the signal transducer and activator of transcription (STAT) signaling 
pathway.  
 
Endocytic sorting of EGF-R 
Upon ligand binding, subsequent dimerization and autophosphorylation of EGF-R 
leads to the recruitment of adaptor protein GRB2, which in turn binds to an E3 ubiquitin-
protein ligase Cbl (Casitas B-lineage Lymphoma). EGF-R can be either mono- or poly-
ubiquitinated by Cbl (Levkowitz et al., 1998), and then recognized and bound by 
ubiquitin-binding proteins of the clathrin coat, such as epidermal growth factor receptor 
substrate 15 (EPS15) (Hawryluk et al., 2006) and hepatocyte growth factor-regulated Tyr 
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kinase substrate (HRS). Upon internalization into clathrin-coated pits, EGF-R will then 
be transported to the early endosome, and subjected to either recycling back to the plasma 
membrane or lysosomal degradation. In the early endosome, EGF-R that is designated for 
lysosomal degradation is still associated with Cbl, and is continuously being 
ubiquitinated. Ubiquitinated EGF-R can then be recognized by ESCRT complexes 
(HRS/STAM and ESCRT-I to III), which mediate receptor translocation into intraluminal 
vesicles (ILVs) of multivesicular bodies (MVBs) or lysosomes for degradation processes 
(Katzmann et al., 2002). However, ubiquitination of EGF-R by Cbl is considered an 
essential step for EGF-R degradation, but not an absolutely required event for clathirin-
mediated endocytosis (Duan et al., 2003; Huang et al., 2007). 
 
Effects of ligands on EGF-R endocytic sorting 
Seven EGF-R ligands have been described so far: epidermal growth factor (EGF), 
transforming growth factor α (TGFα), heparin-binding EGF (HB-EGF), β-cellulin 
(BTC), amphiregulin (AR), epiregulin (EPI), and epigen. In regards to ligand mediated 
EGF-R endocytosis and degradation, both EGF and TGFα have been studied extensively. 
Unlike EGF that binds to EGF-R, which leads to lysosomal degradation of EGF-R, the 
binding between TGFα and EGF-R causes receptor recycling (Decker, 1990). This is the 
reason that TGFα is a stronger mitogen than EGF (Waterman et al., 1998). It is believed 
that the binding between EGF and EGF-R is relatively stable in the acidic environment of 
endosomes, compared to the binding between TGFα and EGF-R. Once TGFα binds to 
EGF-R and targets EGF-R into the endosome, the binding between TGFα and EGF-R 
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quickly dissociates due to the low pH in endosome, leading to EGF-R de-phosphorylation 
and de-ubiquitination. Deubiquitinated EGF-R will then be recycled back to the plasma 
membrane (Longva et al., 2002). Interestingly, one study on amphiregulin mediated 
effects of EGF-R degradation suggests that amphiregulin stimulation results in EGF-R 
recycling rather than degradation, even in the condition that Cbl is overexpressed and 
EGF-R is extensively ubiquitinated (Stern et al., 2008). Furthermore, many studies have 
indicated that high expression levels of amphiregulin could be used as a marker to select 
patients for anti-EGF-R therapy. For example, metastatic colorectal cancer patients with 
high expression levels of amphiregulin and epiregulin are more sensitive to anti-EGF-R 
antibody cetuximab treatment (Khambata-Ford et al., 2007). In addition, it has been 
suggested that NSCLC patients with wild-type EGF-R and positive for amphiregulin may 
obtain a clinical benefit from EGF-R tyrosine kinase inhibitor treatment (Chang et al., 
2011). 
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CHAPTER 2 
RATIONALE AND DISSERTATION OUTLINE 
Lung cancer is the leading cause of cancer related deaths in the United State and 
worldwide. Each year, the number of mortalities due to lung cancer is more than that of 
colon, breast, and prostate cancers combined. Due to the lack of early detection method, 
NSCLC is often diagnosed at advanced or metastatic stages. So far, chemotherapy is still 
the first line of therapy to treat advanced or metastatic NSCLC (see Table 1.2 for a full 
list of standard treatments for NSCLC). However, the standard third-generation platinum-
based doublet agents, even in combination with targeted therapy agents, only result in a 
small improvement for patients with advanced NSCLC. Therefore, the identification of 
new therapeutic targets and discovery of new combinational therapeutic regimens to treat 
NSCLC are of extreme importance. In addition to the unsatisfactory results of the current 
therapeutic regimens in NSCLC, the hypoxic tumor microenvironment presented in all 
solid tumors, including lung cancer, adds another layer of difficulty to the development 
of therapeutic agents targeting advanced NSCLC.  Notably, it has been shown that the 
cells present in hypoxic tumor regions are responsible for resistance to 
chemo/radiotherapies. Moreover, hypoxia has been linked with many other effects in 
promoting tumor growth and metastasis, such as increased angiogenesis, enhanced 
metastatic potential, DNA replication and reduced protein synthesis. Therefore, the 
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purpose of this dissertation is to identify potential therapeutic targets for the treatment of 
advanced NSCLC under hypoxic conditions.  
We and other groups have shown that Notch signaling plays a crucial role in 
NSCLC. Notch signaling is an evolutionarily conserved signaling pathway that has been 
extensively studied in cell fate regulation and stem cell homeostasis. Notch signaling is 
frequently dysregulated in human cancers. In mammals, there are four Notch receptors 
(Notch-1 to 4) and five canonical Notch ligands, which include three Delta-like and two 
Jagged. In T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), Notch-1 is activated 
through chromosomal translocations (Ellisen et al., 1991) or activating mutations (Weng 
et al., 2004). Similarly, increased Notch activity has also been observed in one third of 
NSCLCs, either due to loss of expression of a negative regulator Numb or gain-of-
function mutations in the Notch-1 gene (Westhoff et al., 2009). Additionally, high 
expression levels of Notch targets Hes-1, HeyL and Hey-1 have been found in a number 
of NSCLC cell lines (Collins et al., 2004), which further suggests the important role of 
Notch activity in NSCLC. Moreover, the importance of different Notch receptor isoforms 
in maintaining tumor growth and promoting tumorigenesis has also been investigated in 
NSCLC. The activity of Notch-3 is linked with increased proliferation of NSCLC cells 
(Konishi et al., 2007) as well as enhanced tumorigenic potential in a subpopulation of 
self-renewing NSCLC stem-like cells (Sullivan et al., 2010). Our previous results showed 
that Notch-1 activity is activated in hypoxia, which is critical in providing survival 
signals to NSCLC cells. Furthermore, targeting Notch-1 signaling by either GSI or 
siRNA against Notch-1 caused significant cell death, specifically under hypoxic 
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conditions (Chen et al., 2007). All of the above studies have elucidated an emerging but 
critical role of Notch signaling in NSCLC, and have also highlighted the therapeutic 
potential of targeting Notch signaling in the treatment of NSCLC.  
To better understand the detailed mechanism underlying Notch-1 mediated 
survival of NSCLC cells under hypoxia, and to develop new potential therapeutic agents 
to treat hypoxic NSCLC, our lab focused on studying the downstream signaling events 
that are activated by Notch-1 signaling and contribute to cell survival under hypoxia 
condition. We found that Notch-1 provides necessary survival signals to NSCLC cells by 
positively regulating insulin-like growth factor-1 receptor (IGF-1R) to activate the Akt-1 
pathway. This effect is exacerbated by the fact that Notch-1 represses phosphatase and 
tensin homolog (PTEN) expression (Eliasz et al., 2010).   
IGF-1R is a transmembrane glycoprotein consisting of two extracellular subunits 
and two intracellular subunits. The two intracellular subunits contain the tyrosine kinase 
domain that is responsible for the activation of downstream signaling components IRS-
1/PI3K/AKT pathway and the Ras/Raf/MAPK pathways. The activation of these 
pathways leads to cell proliferation, promotes transformation, survival and migration. 
High expression level of IGF-1R has been detected in patients with advanced NSCLC. In 
NSCLC, IGF-1R signaling is involved in cell proliferation, tumor invasion and survival. 
In addition to our finding that IGF-1R is a target of Notch-1 in NSCLC cells, the 
crosstalk between IGF-1R and Notch pathways in T-ALL has recently been reported, 
which also suggests that Notch signaling promotes tumor growth and survival through 
regulating IGF-1R expression (Medyouf et al., 2011). The same group also reported that 
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the expression of IGF-1R is regulated by Notch in T-ALL through microRNA miR-223 
(Gusscott et al., 2012).  Interestingly, IGF-1R downstream signaling PI3K/Akt/mTOR 
has been shown to regulate the levels of HIF-1α in different types of cancer. In prostate 
cancer and glioblastoma-derived cell lines, Akt activation leads to increased HIF-1α 
expression, whereas PTEN attenuates hypoxia-mediated HIF-1α expression (Zhong et 
al., 2000; Zundel et al., 2000). On the other hand, HIF-1α protein translation was 
elevated upon activation of PI3K/Akt/mTOR pathway in breast cancer (Laughner et al., 
2001). Since the intracellular Notch (NICD) was shown to be stabilized and activated by 
binding to HIF-1α (Gustafsson et al., 2005), not only IGF-1R signaling can be activated 
by Notch, the Notch downstream signaling may also be triggered by IGF-1R signaling 
through regulating the level of HIF-1α, to form a positive feedback loop. Therefore, an 
inhibitory antibody targeting the IGF-1R or a pan Akt inhibitor may synergistically act in 
combination with GSI (a γ-secretase inhibitor that blocks Notch signaling) to completely 
inhibit the IGF-1R and Akt signaling pathways, and contribute to depletion of tumor 
mass in hypoxic areas, thus providing advantages to the treatment of advanced NSCLC. 
The overall hypothesis of this dissertation is that γ-secretase inhibitor (GSI), MRK-
003, or a fully humanized antibody against the human IGF-1R that promotes the receptor 
degradation (IGF-1R inhibitory antibody), MK-0646, or a pan-Akt inhibitor, MK-2206, 
alone or in various combinations, could improve the efficacy of chemotherapy for 
advanced NSCLC. We tested this hypothesis in mouse preclinical models of orthotopic, 
advanced (metastatic) NSCLC, since the stage IV NSCLC patients who receive the best 
supportive therapy alone has a median survival of 3.5 months. To parallel this situation 
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we should have started therapy in mice with a life expectancy of about 2.7 days at the 
time of intervention. We arbitrarily started therapy when mice had a bit more than a week 
of life expectancy (8 or 9 days). 
In Aim 1, we wanted to test whether inhibition of the Notch-1/IGF-1R/Akt 
axis is a suitable therapeutic tool to target hypoxic NSCLC. Specifically, we tested 
this hypothesis by using a number of drugs that inhibit Notch-1, IGF-1R, or Akt, as well 
as some other drugs currently in clinical use either as standard of care or second line 
therapeutics (cisplatin and erlotinib). We tested these drugs in an orthotopic mouse model 
of advanced NSCLC. We sought to determine the best drug combination that improves 
the median survival of mice with advance NSCLC. We used the orthotropic model 
instead of a subcutaneous xenograft model because this model can better recapitulate the 
hypoxic environment of tumors grown in the lungs, which are more heterogeneous and 
contain hypoxic areas in combination with well-oxygenated tumor tissues. In our 
experience, a subcutaneous xenograft is mostly hypoxic, hence less heterogeneous in 
terms of tumor microenvironment. Additionally, we also wanted to test whether the 
hypoxic tumor region is indeed decreased and if cancer metastasis is reduced after drug 
treatments. Specifically, we measured the expression levels of hypoxic markers (human 
VEGF-A and GLUT-1) in tumors excised from GSI treated and vehicle treated mice. 
Both VEGF-A and GLUT-1 are known HIF specific target genes (Carroll and Ashcroft, 
2006; Schipani et al., 2009), and we also identified GLUT-1 as a good marker of hypoxia 
in NSCLC. Using the TUNEL assay, we visualized specific cell death in hypoxic tumor 
areas.  Furthermore, we quantified the tumor burdens in the lungs, livers and brains of 
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mice by measuring the ratio of genomic human versus mouse Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) by quantitative PCR (the assay was previously 
validated using known number of cells). 
During the course of treating tumor-bearing mice with IGF-1R inhibitory 
antibody (MK-0646), we found that at the beginning of the treatment, MK-0646 had a 
tumoristatic effect on NSCLC cells. However, after the first two weeks, tumor cells 
resumed growth and ultimately led to the death of the experimental animals. The 
recurrent malignancy and eventual fatality are commonly seen in anti-cancer therapy in 
humans (with the exception of some hormone-driven malignancies). Regardless of the 
therapeutic approach, tumors become resistant to adjuvant radio/chemotherapy and 
eventually lead to the death of the patients. In Aim 2 of this dissertation, our objective 
was to uncover the mechanism(s) that allow cancer cells to evade IGF-1R 
deprivation. A recent study suggested that inhibition of Akt-1 signaling leads to a 
compensatory activation of several receptor tyrosine kinases (RTKs) (Chandarlapaty et 
al., 2011). Since our preliminary results showed that treatment with MK-0646 in NSCLC 
cells caused rapid loss of IGF-1R total protein and dramatic loss of Akt activation, we 
wanted to investigate if tumor cells evade MK-0646 treatment through activating 
alternative RTKs. Proteomic RTK array analysis with lung tumor samples from mice 
treated with IGF-1R inhibitory antibody (MK-0646) showed that the level of 
phosphorylated EGF-R (pEGF-R) was significantly increased compared to vehicle 
controls. As activation of the EGF-R signaling pathway leads to cell survival and 
proliferation, this could be a potential mechanism underlying the tumor survival when 
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IGF-1R signaling is impaired. In Aim 2, we hypothesized that IGF-1R inhibitory 
antibody treatment activates the EGF-R signaling pathways, leading to tumor cell 
survival and proliferation. This hypothesis was tested both in vitro, using NSCLC cell 
lines cultured in MK-0646 containing media, and in vivo, with lung tumor samples 
obtained from MK-0646 treated mice. Furthermore, we also wanted to further advance 
this study by identifying the detailed molecular mechanisms that lead to EGF-R 
activation. We focused on determining if EGF-R mRNA or protein levels were affected, 
whether the levels of EGF-R ligands were changed and whether the EGF-R endocytosis 
pathway was altered by MK-0646 treatment.  
Since NSCLC cells treated with MK-0646 had overactivated EGF-R, we asked 
whether such cells could have become more sensitive to the EGF-R inhibitor (erlotinib). 
In Aim 3, we hypothesized that administration of the IGF-1R inhibitory antibody 
followed by the EGF-R inhibitor (erlotinib) has better efficacy in treating advanced 
NSCLC. This hypothesis was again tested both in vitro and in vivo. Briefly, NSCLC cells 
were cultured in MK-0646 containing media for three weeks to activate EGF-R signaling. 
Then the cells were either treated with the EGF-R inhibitor (erlotinib) or transduced with 
a lentiviral vector expressing shEGF-R to stably knock down EGF-R. Cell viability 
relative to vehicle treatment was then assessed. We also compared the median survival of 
mice treated with sequential therapy (MK-0646 for three weeks and then erlotinib) to 
each single agent and to a to a combination therapy protocol (MK-0646 plus erlotinib 
from the beginning of treatment). 
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Inhibiting Notch-1 through a GSI or other pharmacological interventions in non-
small cell lung cancer may preferentially target hypoxic areas and the tumor-initiating 
cells within them. The crosstalk between Notch-1 and IGF-1R signaling suggests a 
possible positive feedback loop with these signaling pathways. For this reason, the use of 
Notch inhibitors in combination with inhibitors of the IGF-1/Akt pathway and/or 
cytotoxic chemotherapy may result in synergistic anti-tumor effects in NSCLC. Also, 
elucidating the detailed mechanisms by which tumor cells evade from the IGF-1R 
depletion could reveal new therapeutic targets for the treatment of this deadly 
malignancy. In conclusion, data obtained by this project provide knowledge on designing 
novel therapeutic regimens to target advanced NSCLC, emphasizing the hypoxic tumor 
regions that are responsible for chemo/radiotherapy resistance and tumor relapse. The 
related signaling pathways and specific AIMs of this dissertation are summarized in the 
following flowchart:  
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Figure 2.1 Dissertation outline. Aim1: Determine whether inhibition of the Notch-
1/IGF-1R/Akt axis is a suitable therapeutic tool to target hypoxic NSCLC. Aim2: 
Delineate the detailed mechanism by which tumor evasion occurred during IGF-1R 
inhibitory antibody treatment. Aim3: Study if administration of IGF-1R inhibitory 
antibody sensitizes NSCLC cells to EGF-R inhibition. 
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CHAPTER 3 
MATERIALS AND METHODS 
Cell Culture 
NSCLC cells (A549, H1437, H226, H1299 and H1650) were grown in RPMI 
1640 supplemented with 5% or 10% fetal bovine serum (FBS). All cell lines were 
fingerprinted using the GenePrint fluorescent STR system (Promega, Madison, WI). Prior 
to injection in mice, A549 and H1437 were transduced with a lentivirus expressing 
luciferase (ViraPowerTM T-Rex Lentiviral expression system, Grand Island, NY; see 
below for cloning details). Some experiments were performed in cell lines re-derived 
from mouse lung tumors obtained through mechanical dissociation of tumor nodules after 
necropsies. After 5 passages, cell lines contained 100% human cells as assessed by Q-
PCR using species-specific primers for GAPDH. For experiments in hypoxia, cells were 
grown in 1% O2, 5% CO2, 94% N2, maintained in chambers (Stem Cell Technologies, 
Vancouver, BC, Canada) filled with a certified, aforementioned mixture of gases (Airgas 
North Central, West Chicago, IL, USA) at 37°C. MiniOX1 oxygen meters (Mine Safety 
Appliances Company, Pittsburgh, PA, USA) were used to measure oxygen concentration. 
 
Reagents 
γ-secretase inhibitor MRK-003, the humanized monoclonal IgG1 antibody against 
IGF-1R MK-0646, and the pan-Akt inhibitor MK-2206 were a generous gift from Merck 
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& Co. (Whitehouse Station, NJ). Erlotinib (N-3-ethylnylphenyl)-6,7-bis(2-
methoxyethoxy)-4 quinazolinamine) was donated by patients of the Loyola University 
Chicago Medical Center who had become unresponsive to it. IGF-1 was from Insight 
Genomics (Fall Church, VA). Cisplatin and NH4Cl were from Sigma-Aldrich (St. Louis, 
MO). MG-132 was from Calbiochem (San Diego, CA). The working concentrations and 
the duration of exposure used in each experiment are specified in the text and in figure 
legends. 
 
Mouse procedures 
Five-week-old female NOD.CB17-Prkdcscid/J mice (Jackson Laboratories, Bar 
Harbor, ME) were injected in the tail vein with 2.5 × 106 cells in 100 µl of sterile saline 
solution. Mice were housed in a pathogen-free animal facility at Loyola University 
Medical Center. All procedures were performed in accordance with the Institutional 
Animal Care and Use Committee of the Loyola University Chicago Medical Center. 
Animals were treated as indicated in the text and were monitored daily until they reached 
one of the end points (observed: dyspnea or 20% weight loss). At the time of euthanasia, 
human cells comprised 93% ± 0.8% of the total lungs of the mice. Tumor burden 
quantification was performed using bioluminescence imaging (Xenogen Vivo-Vision 
IVIS 100 In Vivo Imaging System, Caliper Life Science, Hopkinton, MA) and by qPCR 
measuring human versus mouse GAPDH after euthanasia. Mice were monitored weekly 
for bioluminescence. All data analysis was performed with the Living Image 3.2 
Software (Caliper) after intraperitoneal injection (i.p.) of 0.25 mg of D-luciferin (Gold 
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Biotechnology, St Louis, MO) into animals under isoflurane anesthesia. Quantitative 
PCR (qPCR) was performed using human and mouse specific GAPDH primers designed 
after sequence alignments of human and GAPDH genomic regions (Clustalw software) to 
discriminate the 2 genes (Table 3.1). Primers were carefully validated, and calibration 
curves to match qPCR results to cell number were developed. Lungs, livers, and brains 
were dissected and flash frozen for molecular analyses. Genomic DNA from these tissues 
was purified using DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) according to the 
manufacture’s protocol.  
 
Table 3.1 Primers used for human and mouse specific GAPDH 
 
Gene Primer Sequence (5’ to 3’) Accession # Targeted Position 
h-GAPDH Fw AGGCCCCGGGATGCTAGTG NC_000012 1486-1864 
h-GAPDH Rev CACACGCGACTCCACCCATC NC_000012 1993-2012 
m-GAPDH Fw AGCACAACTCAAAACTACCTGCA NW_001030907.1 3202-3225 
m-GAPDH Rev TGAGGTGTTTTGCTCCCAGT NW_001030907.1 3332-3351 
 
 
 
Plasma glucose concentration was measured from 100 µl of blood drawn from the 
lateral tail vein of mice prior euthanasia using the Glucose Assay Kit (Eton Bioscience 
Inc., Cambridge, MA) following the manufacturer’s instructions. 
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Cell Lysis, Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western Blotting 
Cells growing in 10 cm diameter dishes were rinsed once with cold PBS and lysed 
on ice in 300 µl of RIPA buffer (0.1% SDS, 1% NP-40, 200uM PMSF, 0.5% sodium 
deoxycholate, 0.2 mM sodium vanadate, 50 mM sodium fluoride, protease inhibitor 
cocktail (Sigma-Aldrich) and phosphatase inhibitor cocktail (Sigma-Aldrich) in PBS). 
Cells then were harvested using a cell scraper and transferred to a 1.5 ml tube on ice, 
followed by sonication and centrifugation at 13,000 rpm for 10 min. Supernatants were 
collected in new tubes after centrifugation, and Bradford assays were used to determine 
the protein concentration. Then, 50-100 µg of protein lysates were mixed with a 2x 
sample buffer (100mM Tris-HCl pH6.8, 4% SDS, 0.2% (wt/vol) bromophenol blue and 
20% glycerol), boiled for 5 min at 95°C, and loaded onto 10% SDS-polyacrylamide gel 
along with a molecular weight marker (PageRuler Plus Prestained Protein Ladder, 
Thermo Scientific, Product# 26619). Samples were electrophoresed in running buffer (25 
mM Tris, 192 mM glycine and 0.1% SDS) at 120 volts at room temperature (RT) using a 
Mini-PROTEAN 3 system (Bio-Rad). Separated proteins were then electrophoretically 
transferred onto Hybond-C Extra nitrocellulose membrane (Amersham Biosciences) in 
transfer buffer (25 mM Tris, 192 mM glycine, 0.37% SDS and 20% (vol/vol) methanol) 
at 300 mA overnight at 4°C. After transfer, membranes were blocked with 5% (wt/vol) 
non-fat milk made in TBST (Tris buffered saline containing Tween-20; 20 mM Tris pH 
7.6, 137 mM NaCl, 0.1% (vol/vol) Tween-20) for 1 hr at RT on a rocking platform 
shaker. After blocking, the membranes were incubated with the appropriate primary 
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antibody diluted in 5% milk-TBST for 2 hr at RT or overnight at 4°C while rocking. 
Following incubation, the membranes were washed 3 times (5 minutes each) with TBST 
and then incubated for 45 min at RT with the appropriate secondary antibody conjugated 
with horse radish peroxidase (HRP) made in 5% milk-TBST. Finally, blots were washed 
5 times (10 min each) with TBST at RT and developed by incubating with enhanced 
chemiluminescence (ECL) reagent (SuperSignal West Dura Extended Duration Substrate, 
Prod# 34076, Thermo Scientific) and exposed to x-ray films (Denville Scientific Inc.) 
using an automated film processor. As an additional control for equal loading, 
nitrocellulose membranes were stained with Ponceau S solution (Sigma-Aldrich).  
 
Chromatin Immunoprecipitation (ChIP) 
Cells were grown to ~80-90% confluency in a 150 mm culture dish containing 20 
ml of growth media. Then the Magna ChIP A immunoprecipitation Kit (Millipore, 
Catalog # 17-610) was used for the ChIP experiments. To crosslink proteins and DNA, 
550 µl of 37% formaldehyde was added to 20 ml of cell culture media (1% final 
concentration), and incubated at room temperature (RT) for 10 min. After crosslinking, 
the unreacted formaldehyde was quenched using 2 ml of 1.25 M glycine at RT for 5 min. 
Then the dishes were placed on ice, washed with 20 ml of PBS twice, and harvested in 2 
ml of cold PBS containing protease inhibitor cocktail II by scraping. Cells were then 
centrifuged at 800 x g at 4°C for 5 min, and the cell pellets were resuspended in 0.5 ml of 
Lysis Buffer containing Protease Inhibitor Cocktail II. To completely lyse the cells, cell 
lysates were incubated further on ice for 15 min, with vortexing every 5 min. 
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Supernatants were then removed after centrifugation at 800 x g at 4°C for 5 min, and cell 
pellets were resuspended in 0.5 ml of Nuclear Lysis Buffer containing Protease Inhibitor 
Cocktail II. To shear crosslinked DNA, the cell lysates were sonicated on ice for 8 
seconds, 10 times (samples were incubated on ice for 50 seconds between each 
sonication). A 5 µl aliquot of sheared DNA was collected for agarose gel (2%) analysis to 
determine the efficiency of sonication. Then, 50 µl aliquots of crosslinked chromatin 
were diluted with Dilution Buffer containing Protease Inhibitor Cocktail II for 
immunoprecipitation (5 µl of the supernatant was removed as the ‘Input’). Chromatin 
was immunoprecipitated overnight at 4°C with rotation using 1 µg of anti-Notch1 (c-20) 
(Santa Cruz Biotech), anti-MAML1 (Millipore), anti-Acetyl Histone H3 (AcH3) 
(Millipore), anti-p300 (H272) (Santa Cruz Biotech) or anti-rabbit IgG (Millipore) 
together with 20 µl fully suspended protein A magnetic beads. The Protein A magnetic 
beads were pelleted with the magnetic separator (Magna Grip Rack (8 well), Cat.# 20-
400) and supernatant was removed. Then the Protein A bead-antibody/chromatin 
complex was washed once with 0.5 ml of each of the following buffers: Low Salt 
Immune Complex Wash Buffer (Cat.# 20-154), High Salt Immune Complex Wash Buffer 
(Cat.# 20-155), LiCl Immune Complex Wash Buffer (Cat.# 20-156), and TE Buffer 
(Cat.# 20-157). Finally, the protein/DNA complex was eluted with ChIP Elution Buffer 
with Proteinase K at 62°C for 2 hours with shaking then 95°C for 10 min. The beads 
were separated from the elution using a magnet and transferred to a new tube. Eluted 
DNAs were then purified using spin columns provided with the Kit and regular PCR or 
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quantitative PCR (qPCR) was performed to determine the presence of CBF-1 binding 
sites (see detailed primer sequences in Table 3.2).  
 
PCR and Quantitative PCR (qPCR) for Chromatin Immunoprecipitation Assay 
The regular PCR and qPCR for Chromatin Immunoprecipitation experiments 
were performed using PTC-200 Peltier Thermal Cycler and ABI 7300 thermal cycler 
(Applied Biosystems), respectively. For standard PCR experiments, each 25 µl reaction 
contained 4 µl ChIP DNA, 12.5 µl of 2X PCR master Mix (Thermo Fisher Scientific) and 
1 µM of forward and reverse primers. PCR reactions were performed using the following 
protocol: 1 cycle at 95°C for 20 minutes, 40 cycles at 95°C for 1 minute and 1 cycle at 
60°C for 20 minutes, followed by 4°C hold. Taqman primers were used in qPCR for the 
ChIP experiment. Each 20 µl Taqman PCR reaction contained 2 µl ChIP DNA, 10 µl of 
2X Taqman master mix (Applied Biosystem), 0.9 µM of forward and reverse primers and 
0.25 µM of probe.  The Taqman PCR reactions were performed as shown below: 1 cycle 
at 50°C for 2 minutes, 1 cycle at 95°C for 10 minutes, and 40 cycles at 95° for 15 seconds 
followed by 1 cycle at 60°C for 1 minutes. 
 
Table 3.2 Primers used for Chromatin Immunoprecipitation (ChIP) Analysis 
 
Gene Primer Sequence (5’ to 3’) Accession # Targeted Position 
Beta-globin-F CCAGCCTTATCCCAACCATA NC_000011.8 328-347 
Beta-globin-R TATCATGCCTCTTTGCACCA NC_000011.8 495-514 
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IGF1R-CBF1-
Up-F TGTGTGTGTCCTGGATTTGG NT_035325.6 See text 
IGF1R-CBF1-
Up-R AGAAACGCGGAGTCAAAATG NT_035325.6 See text 
IGF1R-CBF1-
DWN-F GGTTGCCGAGGGTATGCA NT_035325.6 See text 
IGF1R-CBF1-
DWN-R GTGAAGGCTCAGTCGTGATTTTT NT_035325.6 See text 
IGF1R-CBF1-
DWN-probe 6FAM-TGCCGATTAACTTTG-MGBNFQ NT_035325.6 See text 
 
 
 
Immunofluorescent Microscopy 
We performed immunofluorescent staining experiments on 8 µm thick lung tumor 
sections or NSCLC cells plated in chamber slides. The tumor samples or cells were fixed 
in 3.7% paraformaldehyde in PBS for 15 minutes. After fixation, cells were 
permeabilized with 50 mM NH4Cl in PBS containing 0.1% Triton X-100 for 15 minutes. 
Then the slides were washed 3 times with PBS (5 minutes each), and blocked for 1 hour 
with 5% BSA in PBS containing 0.05% Triton X-100.  Cells were incubated with a 
primary antibody diluted in 1% BSA in PBS containing 0.05% Triton X-100 overnight at 
4°C on a rocking platform (See Table 3.2 for detailed information of antibodies). Rabbit 
IgG or mouse IgG was used as negative control in the step of the primary antibody 
staining. After washing with PBS containing 0.1% Triton X-100 5 times (5 minutes 
each), goat anti-mouse Alexa Fluor 488 (or 568) or goat anti-rabbit Alex Flour 568 (or 
488) was used in the step for the secondary antibody staining. Secondary antibodies were 
also diluted in 1% BSA in PBS containing 0.1% Triton X-100, and the incubation time 
was 1 hour. Finally, cells were washed 5 times with PBS containing 0.1% Triton X-100 
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(5 minutes each), rinsed once with PBS, and mounted with a fluorescence mounting 
medium (Dako, Glostrup, Denmark). The images were acquired with an AX80 
microscope (Olympus, Center Valley, PA, USA). Lenses were UPlanApo (Olympus) 
with a numerical aperture of 10X. The camera was RETIGA 4000R (QImaging, Surrey, 
BC, Canada). The software for image acquisition was Photoshop 6.0 (Adobe Systems 
Inc., San Jose, CA, USA). Images were processed (overlaid) using Illustrator CS software 
(Adobe). 
 
Plasmids and transfections 
The plasmid encoding DN-MAML-1 was described earlier (Weng et al., 2003). 
Transient transfections DN-MAML-1 or control plasmid were transfected into NSCLC 
cells by electrophoresis. Cells were washed 3 times with Opti-MEM to remove any 
remaining serum, the presence of which decreases the efficiency of electroporation. Then 
the cells were transferred into electroporation cuvettes with 2 µg of plasmid per million 
cells, and electrophoresis was performed using an electroporator (GenePulserII, Bio-Rad, 
Hercules, CA, USA) under the following parameters: 300kV, 975 µF. After 
electroporation, cells were quickly resuspended in media containing serum and plated 
into dishes. 
Constitutively active Akt1 (NH2-terminal myristoylatable Akt1, Myr-Akt1) and 
dominant negative Akt1 (K179M mutant Akt1) were cloned into the pUSEamp(+) 
expression plasmid (pUSE empty vector was used as the negative control) (Upstate, 
Millipore, Temecula, MA). Transient transfections were done using Fugene HD 
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(Promega, Madison, WI) according to the manufacturer’s instructions. In brief, cells were 
plated 1 million per 10cm dish one day before the transfection. On the day of the 
transfection, 3 µg of plasmid and 9 µl Fugene HD reagent were incubated together in 150 
µl Opti-MEM for 5 minutes, and added to each well of 6-well plates containing attached 
cells. 
 
Lentiviral systems 
The luciferase gene was excised from pGL2 basic vector (Promega) by restriction 
digestion at the Kpn I and Bam HI sites and ligated into the Kpn I and Eco RI sites of 
pENTR4 (Invitrogen, Grand Island, NY). The incompatibility between the Bam HI and 
Eco RI sites was circumvented using a linker oligonucleotide in the ligation mixture. The 
luciferase sequence was transferred via Gateway recombination into the lentiviral 
backbone plasmid pLenti4/TO/V5-DEST (ViraPower T-Rex Lentiviral Expression 
System, Invitrogen). To produce viruses containing the luciferase gene, 239FT cells were 
cotransfected with ViralPower Mix together with pLenti4/TO/V5-DEST containing 
luciferase using lipofectamine 2000 (Invitrogen). 72 hours after transfection, supernatants 
were collected and viruses were concentrated by ultracentrifugation at 25,000 x g for 1 
hour and 45 minutes at 4°C. Pelleted viruses were then resuspended with RPMI at 4°C 
overnight. To generate luciferase stable expressing cell lines, cells were infected with 
packaged lentivirus, and selected with Zeocin (Invitrogen) as recommended (Invitrogen). 
Dual-Luciferase Reporter Assay System (Promega) was used to verify the expression of 
the luciferase gene, as recommended by the manufacturer, and relative light units (RLUs) 
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were measured using a Femtomaster FB15 luminometer (Zylux Corporation, Maryville, 
TN). 
 Plasmids encoded for lentiviral packaging plasmids, pLKO lentiviral vector and 
pLKO-shEGF-R were gifts from Dr. Takeshi Shimamura. Lentiviruses were packaged in 
293T cells. Briefly, 239T cells were plated as 4 x 106 cells per 10 cm tissue culture dishes 
with 10 ml of DMEM containing 10% FBS one day before the transfection. The 
following day, the culture media was changed to 6ml of DMEM containing 10% FBS 1 
hour before the transfection. The transfection mixture of plasmid DNA and Fugene HD 
transfection reagent (Invitrogen) was prepared according to the manufacturer’s 
instructions. A 1:3 ratio of DNA: Fugene HD reagent was used. Viral packaging plasmids 
pLP1/2 and pLP/VSVG were cotransfected with pLKO-shEGF-R to produce lentiviruses 
expressing shEGF-R. Cell culture media were changed to 6ml of DMEM containing 20% 
FBS per plate and incubated for additional 48 hours to generate viruses. Lentiviruses 
were harvested by centrifugation of culture media at 1500 rpm for 10 minutes and the 
supernatants were collected and added to NSCLC cells. A549 and H1437 cells were 
incubated with lentiviruses expressing either vector control or shEGF-R overnight in the 
incubator and stably transduced cells were selected in growth media supplemented with 
puromycin (3 µg/ml).  
 
Receptor tyrosine kinase (RTK) arrays  
Human Phospho-RTK (Human Phospho-RTK Array Kit, R&D Systems Inc., 
Minneapolis, MN) arrays were used according to the manufacturer’s instructions. Briefly, 
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tumor tissue was washed with cold PBS and homogenated in NP-40 lysis buffer (1% NP-
40, 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM sodium 
orthovanadate, 10 µg/ml Aprotinin, 10 µg/mL Leupeptin, and 10 µg/mL Pepstatin), and 
250 µg of cell homogenate was incubated with preblocked membranes overnight. 
Membranes were subsequently washed and incubated with freshly diluted detection 
antibody (anti-phosphotyrosine-HRP) for 2 hours at room temperature (R.T.) on a 
rocking platform shaker. Spots were detected using enhanced chemiluminescence (ECL) 
(SuperSignal West Dura Extended Duration Substrate, Prod# 34076, Thermo Scientific) 
and exposed to x-ray films  (Denville Scientific Inc.). 
 
RNA isolation and cDNA preparation 
 Total RNA from cultured cells or lung tissue samples was extracted with the 
RNeasy Mini kit (Qiagen, Valencia, CA) according to the manufacture’s protocol. cDNA 
was synthesized with iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad 
Laboratories, Hercules, CA) using oligo (dT) and random primers. Each reaction 
contained 1 µg of RNA, 4 µl of 5x iScript reverse transcription supermix and nuclease-
free water up to a total of 20 µl. The following incubation protocol was used for cDNA 
synthesis: 5 minutes at 25°C followed by 30 minutes at 42°C and then 5 minutes at 85°C. 
No-RT control reactions were also performed with the same amount of total RNA to 
ensure that there was no genomic DNA contamination.  
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Quantitative RT-PCR (qRT-PCR) 
Quantitative RT-PCR to analyze gene expression levels using the previously 
described cDNA was performed with SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA). For each sample, a serial dilution of cDNA template 
was measured in duplicate using 2 µl diluted cDNA, 12.5 µl 2X SYBR Green Master 
Mix, 0.2 µM each forward and reverse primers and nuclease-free water up to a total of 25 
µl. The standard SYBR Green PCR reaction cycles were run in an ABI 7300 thermal 
cycler (Applied Biosystems) as follows: 1 cycle at 95°C for 20 minutes and 40 cycles at 
95°C for 1 minute and 1 cycle at 60°C for 20 minutes.  No-RT reactions were used as 
negative controls for templates. The detailed primer sequences are described in Table 3.3. 
Relative expression levels of all analyzed genes were normalized to human ribosomal 
protein RPL13A expression levels. Experiments were repeated three times.  
 
Table 3.3 Primers used for quantitative RT-PCR (qRT-PCR) analysis 
 
Gene Primer Sequence (5’ to 3’) Accession # Targeted Position 
h-EGF-R Fw CTTGCCGCAAAGTGTGTAAC NM_005228.3 1241-1260 
h-EGF-R Rev TGTGGATCCAGAGGAGGAGT NM_005228.3 1415-1396 
h-ErbB3 Fw TAGCCAGCTGTCCCCATAAC NM_001982 1136-1155 
h-ErbB3 Rev TGTTGCTCGAGTCCACAGTC NM_001982 1318-1299 
h-amphiregulin 
Fw TGGTGCTGTCGCTCTTGATA NM_001657.2 242-261 
h-amphiregulin 
Rev CCCTGAAGACATCTCACTTCTT NM_001657.2 390-369 
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h-EGF Fw CGTGCCCTGTAGGATTTGTT NM_001178131.1 1468-1487 
h-EGF Rev GAGCTGGCTACATCCACCAT NM_001178131.1 1676-1657 
h-HB-EGF Fw AGAAGAGGGACCCATGTCTT NM_001945.2 583-602 
h-HB-EGF Rev AGGATGGTTGTGTGGTCATAG NM_001945.2 763-743 
h-betacellulin 
Fw GCAGCTACCACCACACAATCA NM_001729.2 507-527 
h-betacellulin 
Rev CCAGAATCTGTCCTCTGTCTCCT NM_001729.2 708-686 
h-TGF-α Fw TTAATGACTGCCCAGATTCCCA NM_001099691.2 375-396 
h-TGF-α Rev CAACGTACCCAGAATGGCAGA NM_001099691.2 479-459 
h-RPL13A Fw CATAGGAAGCTGGGAGCAAG NM_012423 749-768 
h-RPL13A Rev ACAAGATAGGGCCCTCCAAT NM_012423 915-896 
h-VEGF-A Fw ATGACCCAGTTTTGGGAACA NM_001025366 2383-2402 
h-VEGF-A Rev TCCTGAATCTTCCAGGCAGT NM_001025366 2600-2581 
h-GLUT-1 Fw GTCGGAGTCAGAGTCGCAGT NM_006516 401-420 
h-GLUT-1 Rev GGCATTGATGACTCCAGTGTT NM_006516 630-611 
h-Hey-L Fw CATAGAGAAACGGCGTCGAGA NM_014571 201-221 
h-Hey-L Rev CGAAAACCAATGCTCCGGAA NM_014571 416-397 
h-Hey-1 Fw TCCTGCCTCCTTCTCTTTGA NM_012258 2034-2053 
h-Hey-1 Rev TCCTGCCTCCTTCTCTTTGA NM_012258 2140-2121 
HK-2 Fw GGCTGTGGATGAGCTTTCACTC NM_000189.4 4107-4128 
HK-2 Rev CGATTTCACCAAGCGTGGA NM_000189.4 4221-4203 
PDK-2 Fw CTGTGACCACCACATGACG NM_002611.4 2416-2434 
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PDK-2 Rev CTGTCTGCTCCAGTTGTTGG NM_002611.4 2593-2574 
ALDOA Fw CTGCCCCCTCCCACTCTT NM_000034.3 2221-2238 
ALDOA Rev GCTGTTTATTTGGCAGTGTGC NM_000034.3 2371-2351 
 
 
 
Histological study (Haematoxylin and eosin) 
 Frozen tissue sections of 8-µm thickness were fixed in 10% formalin for 10 
minutes followed by rinsing with PBS and H2O before staining. Slide sections were 
incubated with Haematoxylin for 5-9 minutes and rinsed with running tap water for 3 
minutes. Then the sections were incubated with 1 or 2 dips 0.3% acid alcohol (1 ml of 
concentrated HCl in 400 ml of 70% ethanol) for differentiation, and rinsed with running 
tap water for 3-4 minutes to remove over-staining. Sections were then incubated in 0.3% 
ammonium hydroxide for 30 seconds to 1 minute followed by rinsing with running tap 
water for 2 minutes. The sections were then incubated in 95% ethanol for 1 minute 
followed by Eosin for 30 seconds to 1 minute. They were then dipped 10-15 times in 
95% ethanol, then dipped 10-30 times in 100% ethanol, and incubated in 100% ethanol 
for 20-30 seconds. Slide sections were immediately incubated in Xylene for 2 minutes 
and another 5 minutes with fresh Xylene followed by mounting with Permount Mounting 
Medium.  
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Protein phosphorylation expression and analysis 
Western blot analyses were performed as previously described. Cells were lysed 
in NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% 
glycerol, 2 mM EDTA, 1 mM sodium orthovanadate, 10 µg/ml Aprotinin, 10 µg/mL 
Leupeptin, and 10 µg/mL Pepstatin). For immunoprecipitation, lysates were incubated 
overnight at 4°C with a specific anti-EGF-R primary antibody followed by a 1-hour 
incubation with Protein G-agarose beads (Santa Cruz Biotech, CA). Then the beads were 
washed 4 times in lysis buffer, and a 2x sample buffer (100mM Tris-HCl pH6.8, 4% 
SDS, 0.2% (wt/vol) bromophenol blue and 20% glycerol) was added and boiled for 5 
minutes at 95°C to dissociated precipitated proteins from the beads. The 
immunoprecipitates were resolved by 8% SDS-PAGE, and blotted for phosphorylated 
Tyrosine HRP (pTyr-HRP) (R&D Systems) and EGF-R (NeoMarkers). 
 
Cell surface biotinylation  
For biotinylation of cell membrane proteins, cells were washed with ice-cold PBS 
and then incubated for 1 hour at 4°C with Sulfosuccinimidobiotin (EZ-Link Sulfo-NHS-
Biotin; Pierce Biotechnology, Rockford, IL) freshly dissolved in H2O (2 mM final 
concentration). The reaction was blocked by rinsing the cells 3 times with 100 mM 
glycine in PBS. Cell lysates were incubated for 1 hour at 4°C with streptavidin-agarose 
(Sigma-Aldrich) to pull down biotinylated membrane proteins. The supernatant was 
stored for further manipulation (first fraction). Streptavidin-biotin complexes (surface 
protein-enriched fraction) were incubated overnight at 4°C with a primary antibody 
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specific for EGF-R. The suspension was then incubated for 1 hour with protein A 
conjugated to magnetic beads (Millipore), and immunocomplexes were captured using a 
dedicated magnet. To estimate the amount of EGF-R not biotinylated (therefore not 
present on the plasma membrane), the first fraction was immunoprecipitated using an 
antibody specific for EGF-R. 
 
Cell viability and proliferation 
NSCLC cells were plated in 100 µl of RPMI with 5% FBS into 96-well cell 
culture plates (5,000 cells/well). Cell viability was determined by using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell MTT assay kit (Roche) 
according to the manufacturer’s instructions. Briefly, 10 µl of MTT labeling reagent was 
added to each well and incubated at 37°C for 4 hours in the incubator. Then 100 µl 
solubilization solution was added and incubated at 37°C overnight. The 
spectrophotometric absorbance was measured at 575 nm using a fluorescent multiplate 
reader (Polar Star Omega, Ortemberg, Germany). The results were expressed as mean ± 
SD of 3 independent experiments. In parallel, dye exclusions and cell count assays were 
performed. Proliferation was analyzed by bromodeoxyuridine (Br-dU) incorporation 
(FITC BrdU Flow kit, BD Pharmingen, San Diego, CA)/7-aminoactinomycin D (7-AAD, 
Sigma-Aldrich) staining. Briefly, 100 µl of BrdU (1mM in DPBS) was added to each 10 
cm dish of experimental NSCLC cells containing 10ml of culture media, allowing 4 
hours incubation time for the incorporation to occur. One million cells were then 
harvested in FACs tubes, washed once with Staining Buffer (1 x DPBS + 3% heat 
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inactivated Fetal Bovine Serum + 0.09% sodium azide) followed by fixation and 
permeabilization with 100 µl of BD Cytofix/Cytoperm Buffer for 15 minutes at room 
temperature and washed once with 1ml of 1 x BD Perm/Wash Buffer. Then cells were 
incubated with 100 µl BD Cytoperm Plus Buffer for 10 minutes on ice, washed once with 
1 x BD Perm/Wash Buffer, and followed by re-fixation with 100 µl of BD 
Cytofix/Cytoperm Buffer for 5 minutes at room temperature and washed with 1 x BD 
Perm/Wash Buffer. After fixation and permeablization, the cells were treated with 100 µl 
of DNase (300 µg/ml) to expose incorporated BrdU for 1 hour at 37C, and washed with 1 
x BD Perm/Wash Buffer. Then cells were resuspended in 50 µl of BD Perm/Wash Buffer 
containing diluted FITC conjugated anti-BrdU antibody (1:50) for 20 minutes at room 
temperature in the dark, followed by washing the cells with 1 x BD Perm/Wash Buffer. 
For total DNA staining for cell cycle analysis, the cells were resuspended with 20 µl of 
the 7-amino-actinomycin D (7-AAD) solution. Finally, 1 ml of Staining Buffer was 
added to each tube to resuspend cells for FACS analysis. FACS analysis was performed 
using a BD FACS Canto II instrument (Becton Dickinson, San Jose, CA) measuring 
30,000 events for each sample at a rate no greater than 400 events/sec. 
 
Statistical analysis 
We performed statistical analysis by Student’s t test. Values were considered 
statistically significant at P < 0.05 in 2-tailed tests. Survival curves were analyzed using 
the Mantel-Cox and Gehan-Breslow-Wilcoxon tests (Prism 5 software). 
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Table 3.4 List of all antibodies used in this dissertation work 
 
Target Type Company Cat. Number 
Active Notch-1 
(Val1744) Rabbit polyclonal Cell Signaling 2421 
Acetyl Histone H3 Rabbit polyclonal Millipore 06-599B 
IGF1Rβ(C-20) Rabbit polyclonal Santa Cruz Biotech. 713 
GFP Rabbit polyclonal Abcam Ab290 
HIF1α (H-206) Rabbit polyclonal Santa Cruz Biotech. 10790 
IgG Rabbit polyclonal Santa Cruz Biotech. 2027 
IgG Rabbit polyclonal Millipore PP64B 
IgG Mouse polyclonal AbCam 18448 
MAML1 Rabbit polyclonal Millipore AB5975 
Notch-1 (C-20) Rabbit polyclonal Santa Cruz Biotech. 6014 
P300 (H-272) Rabbit polyclonal Santa Cruz Biotech. 8981 
p-Akt (Ser473) Rabbit polyclonal Cell Signaling 4058 
p-Akt (Ser473) 
(D9E) Rabbit monoclonal Cell Signaling 4060 
Akt-1 (G-5) Mouse monoclonal Santa Cruz Biotech. 55523 
pERK 1/2 Rabbit polyclonal Cell Signaling 4370 
ERK 2 Mouse monoclonal Santa Cruz Biotech. 154 
EGF-R Mouse monoclonal NeoMarkers 400-P1ABX 
pTyr-HRP Mouse monoclonal R&D Systems 841403 
Ubiquitin (PD41) Mouse monoclonal Santa Cruz Biotech. 8017 
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Caspase-3 Rabbit polyclonal Cell Signaling 9662 
GLUT-1 Mouse monoclonal Abcam Ab40084 
GAPDH Mouse monoclonal Chemicon MAB374 
AlexaFluor 568 Rabbit IgG labeling kit Zenon Z25306 
AlexaFluor 488 Rabbit IgG labeling kit Zenon Z25302 
AlexaFluor 488 Mouse IgG labeling Zenon Z25002 
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CHAPTER 4 
RESULTS 
Previous work from our laboratory indicates that Notch-1 is activated and 
stabilized by hypoxia inducible factor-1α (HIF-1α) under hypoxic conditions. Activated 
Notch-1 can then provide survival signals to NSCLC cells by positively regulating 
insulin-like growth factor-1 receptor (IGF-1R) to activate the AKT pathway. 
Additionally, this effect is exacerbated by the fact that Notch-1 depresses phosphatase 
and tensin homolog (PTEN) expression. We have also found that inhibition of Notch-1 
signaling in NSCLC cells causes cell death specifically under hypoxia. The results are 
summarized in Figure 4.1. 
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Figure 4.1 Schematic of Notch-1 activation in hypoxia, which provides survival 
signals to NSCLC cells through activating Akt-1. In hypoxic tumor microenvironment, 
HIF-1α  is stabilized. By binding to and stabilizing intracellular Notch-1 (Notch-1IC), 
HIF-1α enhances the transcriptional activity of Notch-1IC, which in turn increases the 
expression IGF-1R and decreases PTEN expression. Both of these events lead to 
hyperactivation of Akt-1, which provides survival signals to NSCLC cells (and possibly 
other solid tumors) specifically under hypoxic conditions. 
 
 
 
Notch-1 directly regulates IGF-1R transcription through its association with the 
+1478 DNA region 
To further investigate the mechanism by which Notch-1 regulates the expression 
level of IGF-1R, we performed experiments with NSCLC cells by transfecting known 
downstream targets of Notch-1: HES-1, HES-5, HEY-1, HEY-L and c-MYC (Palomero 
et al., 2006)). However, none of these targets seemed to regulate the level of IGF-1R, 
neither at the mRNA level nor at the protein level. Therefore, we then thought that 
Notch-1 might regulate the expression of IGF-1R by directly binding to its promoter. We 
have analyzed the sequence in the DNA region surrounding the IGF-1R initiation codon 
(position +1), and found two regions containing canonical RBP-Jkappa/CBF1 consensus 
sequence (CGTGGGAA): one at position -612 and a second at position +1478. A 
schematic overview of these regions is represented in Figure 4.2.  
To this point, we performed chromatin immunoprecipitation (ChIP) experiment 
targeting these two regions using an antibody recognizing Notch-1IC.  We found that 
there is no association of Notch-1IC at region -612 in seven independent experiments. 
Instead, we detected that Notch-1IC was present at region +1478 (Figure 4.3). We then 
performed ChIP experiments on Notch transcriptional coactivators: Mastermind-like-1 
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(MAML-1) (Nam et al., 2006) and p300 (Fryer et al., 2002). The ChIP results suggested 
that both MAML-1 and p300 bind to DNA region +1478 (Figure 4.4a). Furthermore, 
when we transfected NSCLC cells with a plasmid encoding dominant negative MAML-1 
(DN-MAML-1), we did not detect the binding of Notch-1, MAML-1 and p300 at DNA 
region +1478, and the amount of acetylated histone H3 (AcH3) was also significantly 
reduced over that region (Figure 4.4a).  
In the DN-MAML-1 plasmid, the central binding domain of MAML-1 for p300 is 
replaced by green fluorescent protein (GFP) (Weng et al., 2003). Therefore it would not 
be able to bind p300, resulting in less acetylated histone H3. These results suggested that 
a complete coactivator complex containing MAML-1 and p300 was needed to allow 
stable Notch-1IC association with DNA region +1478. Alternatively, the absence of p300 
activity in this site may decrease the overall acetylation of histone H3 (Figure 4.4a), 
leading to a local rearrangement of the chromatin structure that could render this region 
less accessible to transcription factors/coactivators. Furthermore, the transfection of 
NSCLC cells with DN-MAML-1 reduced IGF-1R expression significantly (Figure 4.4b). 
Collectively, the above data suggest that Notch-1 directly regulates IGF-1R transcription 
through its association with the +1478 DNA region. 
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Figure 4.2 Schematic representation of the promoter region of the IGF-1R gene. 
Gray: region upstream of the initiation of transcription; darker pink: 5’ UTR; lighter pink: 
first fragment of the CDS (+1, initiation of translation); green: 5’ region of the first 
intron. Note that there are two canonical CBF-1 binding sites: at regions -612 and +1478. 
(a) At region +1478, but not -612, we detected the association of Notch-1, MAML1 and 
p300. (b) Upon transfection of a plasmid that encodes dominant negative MAML1 (DN-
MAML-1), we no longer detected any association of these proteins at region +1478. 
Additionally, the amount of acetylated histone H3 was significantly reduced.  
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Figure 4.3 Notch-1 associates with the +1478 region of the IGF-1R gene. ChIP 
experiment was performed on A549 cells. DNA fragments were analyzed using end-point 
PCR with specific primers that amplify DNA region +1478 (See Table 3.1 for detailed 
primer sequences). Different pre-immune IgGs were used in this experiment: one from 
Millipore (IgG M) and the other from Santa Cruz Biotechnology (IgG SC). Notch-1 was 
immunoprecipitated using the antibody C20 (Santa Cruz Biotechnology). 
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Figure 4.4 Notch-1, MAML-1 and p300 associate with DNA region +1478 of IGF-1R, 
and transfection of NSCLC cells with plasmid DN-MAML-1 disrupts these 
associations. (a) A549 cells were transfected with either control plasmid (black columns) 
or a plasmid that encodes dominant negative MAML-1 (DN-MAML-1) (gray columns). 
The ChIP experiments were performed using antibodies against acetylated histone H3 
(AcH3), Notch-1, MAML-1 and p300 for immunoprecipitation. The amount of 
associated DNA fragment at region +1478 (62 bp-long products) was quantified with 
Real-Time PCR method using Taqman primers (see Table 3.1 for detailed primer 
sequences).  The IgG column represents the average of three different pre-immune IgGs. 
Each column represents the average of four (black columns) or five (gray columns) 
independent experiments. The IgG column represents nine independent 
immunoprecipitation experiments. (b) Western Blot analysis of A549 cells transfected 
with either control plasmid or DN-MAML-1 (the binding domain for p300 is replaced by 
green fluorescence protein (GFP)). At 24hr after transfection, the protein levels of IGF-
1R were substantially decreased compared to cells transfected with control plasmid. 
Since DN-MAML-1 seemed to be toxic to NSCLC cells following transfection, all the 
experiments shown here were conducted 24hr post transfection. 
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Establishment of mouse orthotopic models with advanced NSCLC 
To generate the orthotopic mouse models, we injected 2.5 x 106 NSCLC cells 
(A549 and H1437) transduced with lentiviral vector expressing firefly luciferase (for 
tumor burden imaging purpose) (see Material and Methods for detailed cloning and 
transduction information) into the lateral tail vein of SCID mice. By intraperitoneal (i.p.) 
injection of the mice with luciferin, the luciferase substrate, we were able to detect the 
tumor cells using a Xenogen luminescence system. Most of the injected cells home to the 
lung, which is the original site of NSCLC development. The presence of tumor cells in 
mice lungs was readily visible 5 minutes after tail-vein injection. The tumor nodules were 
clearly detected throughout the lungs of mice 5-weeks after injection (Figure 4.5a). 
Figure 4.5a shows the upper third of the left lung of a representative mouse (H&E 
staining) at the initiation of therapy. There are two large tumor nodules, indicating the 
advanced tumor progression stage at the time when mice were euthanized. Moreover, we 
transduced A549 cells with the luciferase gene in a lenti-viral vector, and were therefore 
able to detect luminescence after giving luciferin substrate to the mice with lung tumors. 
With this method, we were able to normalize the mice lung tumor burden before the 
initiation of therapy. Before we administered treatment, mice were imaged for light 
emission and only the mice within ±20% of average light emission in thorax and little or 
no light emission at the site of injection were assigned to treatment groups. Figure 4.5b 
shows a representative example of the preliminary imaging analysis to assess equal tumor 
burden prior to therapy initiation.  
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In order to make sure that the tumor burdens of the experimental mice are equal 
before treatments, we performed quantitative PCR analysis at this 5-week time point. 
Specifically, Quantitative PCR using species-specific primers for the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene on total DNA extracted from 12 mice lungs, 
showed that the mean ratio of human/mouse cells of 0.0495 ± 0.0029 (Table 4.1). This 
result suggests that there was minimum tumor burden variation at the beginning of 
therapy.  
In addition to A549 and H1437 cells, we also tried to inject NSCLC cell lines 
H1299 and H838 into the tail veins of these mice. However, neither cell line generated 
acceptable tumor burden in the mice lungs. Five weeks after injection, we could not 
detect any tumor mass in the mice injected with H838, and only detected brain tumors in 
the H1299 injected mice.  
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Figure 4.5 Characterization of lung tumors in advanced NSCLC mice model at the 
time of therapy initiation (5-weeks after tail vein injection). (a) Histopathological 
(H&E) evaluation of an 8 µm-thick lung section (upper third of the left lung lobe) from a 
representative mouse five weeks after tail vein injection of A549 cells. (b) Imaging 
analysis of tumor burden of mice injected with A549 cells prior to therapy. The mice that 
showed substantial light emission at or around the site (tail) of injection were discarded 
from study. 
 
 
 
Table 4.1 Quantitative PCR analysis of the human/mouse GAPDH ratio in the 
whole left lungs of 12 representative animals 5-weeks after tail vein injection. 
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Hypoxia/Notch-1/IGF-1R/Akt-1 axis also takes place in vivo  
Previous findings in our lab suggested that Notch-1 is activated in hypoxia, which 
provided survival signals to NSCLC cells by upregulating IGF-1R expression and 
downregulating PTEN levels. Both of these events led to hyperactivation of Akt-1 
signaling pathway. We wanted to confirm these findings in vivo using a mouse model 
with human metastatic NSCLC (see Material and methods for details). We performed a 
series of co-immunofluorescent staining on snap frozen, 8 µm-thick tissue slides 
containing sections of mice lungs. To stain hypoxic regions in mice lung sections, we 
used glucose transporter-1 (GLUT-1) as a hypoxia marker (Behrooz and Ismail-Beigi, 
1999; Ebert et al., 1995). We confirmed the previous finding that GLUT-1 is a good 
hypoxia marker, since Western Blot and immunofluorescent staining showed elevated 
GLUT-1 levels upon incubating the cells under hypoxic conditions (Figure 4.6). 
Strikingly, co-immunofluorescent staining of sections obtained from tumor-bearing lungs 
of SCID mice injected with A549 cells through the tail vein showed that only hypoxic 
tumor areas expressed Notch-1IC, maximally expressed IGF-1R, and appeared to be the 
only tumor areas in which Akt-1 is phosphorylated (Figure 4.7a-d). By contrast, PTEN 
was never expressed in the tumor hypoxic areas that expressed hypoxic marker GLUT-1 
(Figure 4.7e). These in vivo results are consistent with our previous in vitro findings and 
the hypothesis that Notch-1 is activated under hypoxia, resulting in activation of Akt-1 
through upregulation of IGF-1R and downregulation of PTEN expression.  
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Figure 4.6 GLUT-1 is an effective hypoxia marker in NSCLC cells. (a-d) 
immunofluorescent staining of A549 cells cultured in normoxia (21% oxygen) (a and c) 
and hypoxia (1% oxygen) (b and d) conditions. The primary antibodies used during the 
staining procedure are pre-immune normal rabbit IgG (negative control) (a and b) and 
rabbit anti-GLUT-1 antibody (c and d). (e) Western blot analysis of GLUT-1 and Actin 
(loading control) performed on H1299 cells cultured at the indicated oxygen 
concentrations. 
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Figure 4.7 Activated Notch-1 (Notch-1IC) is expressed in hypoxic tumor cells, 
together with IGF-1R and phosphorylated Akt-1 (Ser473) but not with PTEN. Co-
immunofluorescence stainings of the indicated proteins on 8 µm-thick slides obtained 
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from tumor-bearing lungs of SCID mice injected with A549 cells through the tail vein. 
(a) Co-expression of GLUT-1 and HIF-1α. (b) Co-expression of GLUT-1 and Notch-1IC. 
(c) Expression of IGF-1R is maximal in GLUT-1 expressing (hypoxic) tumor cells. (d) 
Phosphorylated Akt-1 (S473) is detected in GLUT-1 expressing (hypoxic) tumor cell 
only. (e) PTEN is expressed in GLUT-1 negative tumor cell only. Note that GLUT-1 and 
PTEN positive cells appear to be contiguous. This is likely an event due to the lateral, 
asymmetric nature of Notch signaling. Bar, 20 µm. 
 
 
 
AIM1: DETERMINE WHETHER INHIBITION OF THE NOTCH-1/IGF-1R/AKT 
AXIS IS A SUITABLE THERAPEUTIC TOOL TO TARGET HYPOXIC NSCLC 
 
Survival analysis of mice treated with GSI, IGF-1R inhibitory antibody or Akt 
inhibitor, alone or in combination  
Since Notch-1 signaling is activated under hypoxia and provides critical 
prosurvival signals to NSCLC cells by activating IGF-1R/Akt signaling, we questioned 
whether interfering with the Notch-1/IGF-1R/Akt axis could deplete tumor mass in 
hypoxic areas in the established orthotopic, very advanced (metastatic) NSCLC mouse 
model. We performed the in vivo experiment with GSI (MRK-003), an inhibitory 
antibody targeting the IGF-1R (MK-0646), and a pan AKT inhibitor (MK-2206). MRK-
003 interacts with γ-secretase component presenilin and blocks its catalytic properties. 
MK-0646 is a humanized IgG1 monoclonal antibody (mAb) against IGF-1R, which 
induces receptor internalization and degradation (Broussas et al., 2009). There are many 
different IGF-1R monoclonal antibodies (including MK-0646) currently in clinical 
development (phase I to III) of breast, colorectal, pancreatic and lung cancer (Gualberto 
and Pollak, 2009; Hewish et al., 2009; Weroha and Haluska, 2008). Many Phase I and II 
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studies using different monoclonal antibodies against IGF-1R suggested promising 
clinical outcomes and minimal toxicity (Haluska et al., 2007; Karp et al., 2009; Tolcher et 
al., 2009). However, a recent Phase III study using figitumumab (another IGF-1R 
inhibitory antibody) in combination with paclitaxel and carboplatin in NSCLC patient 
showed disappointing activity and metabolic toxicity (mainly hyperglycaemia) (Pollak, 
2012). Therefore, we planned our experiment using MK-0646 in combination with GSI 
that targets hypoxic tumor regions, only in a window of time during therapeutic 
interventions. MK-2206 is a pan Akt inhibitor that interacts with the PH domain and 
prevents Akt interaction with PIP3. 
Notch inhibition results. To inhibit Notch-1 signaling, we used γ-secretase 
inhibitor (GSI) MRK-003 (Merck & Co., Inc., Whitehouse Station, NJ) in this study. The 
therapy regimen was 100 mg/kg of MRK-003 in 0.05% methylcellulose administered via 
oral gavaging three consecutive days a week. The therapy combinations were as follows: 
GSI plus cisplatin (3 mg/kg, one weekly i.p. injection for four consecutive weeks), GSI 
plus the fully humanized monoclonal antibody MK-0646 targeting the human IGF-1R 
(10 mg/kg, one weekly injection). There were 16 experimental animals assigned to each 
treatment group. The results are plotted as survival curves shown in Figure 4.8, left panel, 
while the statistical analysis of median survivals are shown in Table 4.2. Due to the fact 
that we have numerous comparisons between treatment groups  (in total we performed 40 
comparisons), it is difficult to assess the most effective therapeutic regimen because of 
the required Bonferroni correction. Specifically, to determine the best therapeutic 
regimen over other groups of treatments, the drug treatment group should have had a 
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corrected P value of 0.0125 or less. Nonetheless, the statistical analysis indicated that all 
treatments significantly prolonged the median survival of mice compared with mice 
treated with a vehicle (methylcellulose) control. In addition, we observed that 
combination therapies of GSI plus cisplatin and GSI plus MK-0646 were statistically 
better treatment regimens compared to a single agent alone.  
Akt pan-inhibition results. The therapeutic regimen of Akt pan-inhibition was 
80mg/kg (3 consecutive days per weeks) of pan Akt inhibitor MK-2206 (Merck & Co). 
We have tested this dosage in tumor free SCID mice, and this was the maximum tolerated 
dose.  However, in the tumor bearing mice, we found that the MK-2206 treated mice 
reached their endpoint (20% loss of body weight) within 8 days after initiation of therapy. 
This was due to glucose intolerance caused by Akt depletion, since the plasma glucose 
concentration in mice at end point was 316 ± 23 mg/dl (average of 8 mice ± standard 
deviation).   
IGF-1R inhibiton results. To inhibit IGF-1R signaling, we treated tumor-bearing 
mice with IGF-1R inhibitory antibody MK-0646 (Merck & Co) with the same regimen 
described earlier. For the combination therapy, MK-0646 plus erlotinib (100mg/kg, 3 
times per week via oral gavaging) were administered together at the beginning of 
treatment. For the sequential therapy, mice were treated with MK-0646 for three weeks, 
followed by MK-0646 plus erlotinib treatment. The IGF-1R inhibitory antibody MK-
0646 alone substantially improved the median survival of treated mice compared with 
that of vehicle control treated mice. Again, due to the multiple comparisons it is difficult 
to assess the best therapeutic regimen (Figure 4.8 right panel, and statistic analysis of 
  
71 
median survivals are shown in Table 4.2). Interestingly, we found that sequential 
treatment (MK-0646 followed by the addition of erlotinib after 3 weeks) significantly 
prolonged mice survival compared with the combination therapy (MK-0646 plus erlotinib 
from therapy initiation) or a single agent alone. The experiment design and rationales are 
discussed later.  
 
 
 
 
Figure 4.8 Survival curves of mice injected with A549 and H1437 cells treated with 
indicated agents. Median survivals of A549-injected mice (days): control (C), 9.0; 
cisplatin, 12.5; MRK-003 (GSI), 15.5; GSI+cisplatin, 19.5; GSI+MK-0646, 26.0; 
erlotinib, 16.0; MK-0646, 25.50; MK-0646+erlotinib, 15.0; 3 weeks of MK-0646 as 
single agent then combination of MK-0646 and erlotinib, 36.5. Median survivals of 
H1437-injected mice (days): control, 8.0; cisplatin, 21.0; MRK-003 (GSI), 30.0; 
GSI+cisplatin, 38.0; GSI+MK-0646, 42.0; erlotinib, 19.0; MK-0646, 26.0; MK-
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0646+erlotinib, 18.5; 3 weeks of MK-0646 as single agent then combination of MK-0646 
and erlotinib, 35.0. 
 
 
 
Table 4.2 Statistical analysis of the mice survival curves shown in Figure 4.8. 
 
A549 
Median Survival C 9.000; cisplatin 12.50 
Ratio 0.7200 
95% CI of ratio 0.2018 to 1.238 
Hazard Ratio Ratio: 2.435 
95% CI of ratio 1.096 to 5.407 
Log-rank (Mantel Cox) Test Chi square: 4.78; P value: 0.0288 
Gehan-Breslow-Wilcoxon Test Chi square: 4.121; P value: 0.0424 
 
Median Survival C 9.000; GSI 15.50 
Ratio 0.5806 
95% CI of ratio 0.06245 to 1.099 
Hazard Ratio Ratio: 3.718 
95% CI of ratio 1.642 to 8.420 
Log-rank (Mantel Cox) Test Chi square: 9.914; P value: 0.0016 
Gehan-Breslow-Wilcoxon Test Chi square: 8.801; P value: 0.0030 
 
Median Survival C 9.000; GSI+cisplatin 19.50 
Ratio 0.4615 
95% CI of ratio -0.06745 to 0.9905 
Hazard Ratio Ratio: 10.51 
95% CI of ratio 4.260 to 25.92 
Log-rank (Mantel Cox) Test Chi square: 26.08; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 24.79; P value: <0.0001 
 
Median Survival C 9.000; GSI+MK-0646 26.00 
Ratio 0.3462 
95% CI of ratio -0.1720 to 0.8643 
Hazard Ratio Ratio: 21.55 
95% CI of ratio 7.947 to 58.45 
Log-rank (Mantel Cox) Test Chi square: 36.39; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 29.21; P value: <0.0001 
 
Median Survival cisplatin 12.50; GSI 15.50 
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Ratio 0.8065 
95% CI of ratio 0.3064 to 1.307 
Hazard Ratio Ratio: 1.668 
95% CI of ratio 0.7594 to 3.663 
Log-rank (Mantel Cox) Test Chi square: 1.624; P value: 0.2026 
Gehan-Breslow-Wilcoxon Test Chi square: 0.8228; P value: 0.3644 
 
Median Survival cisplatin 12.50; GSI+cisplatin 19.50 
Ratio 0.6410 
95% CI of ratio 0.1311 to 1.151 
Hazard Ratio Ratio: 4.104 
95% CI of ratio 1.738 to 9.690 
Log-rank (Mantel Cox) Test Chi square: 10.38; P value: 0.0013 
Gehan-Breslow-Wilcoxon Test Chi square: 9.620; P value: 0.0019 
 
Median Survival cisplatin 12.50; GSI+MK-0646 26.00 
Ratio 0.4808 
95% CI of ratio -0.01932 to 0.9809 
Hazard Ratio Ratio: 11.47 
95% CI of ratio 4.255 to 30.93 
Log-rank (Mantel Cox) Test Chi square: 23.25; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 21.68; P value: <0.0001 
 
Median Survival GSI 15.50; GSI+cisplatin 19.50 
Ratio 0.7949 
95% CI of ratio 0.2849 to 1.305 
Hazard Ratio Ratio: 2.604 
95% CI of ratio 1.169 to 5.801 
Log-rank (Mantel Cox) Test Chi square: 5.485; P value: 0.0192 
Gehan-Breslow-Wilcoxon Test Chi square: 5.833; P value: 0.0157 
 
Median Survival GSI 15.50; GSI+MK-0646 26.00 
Ratio 0.5962 
95% CI of ratio 0.09606 to 1.096 
Hazard Ratio Ratio: 3.206 
95% CI of ratio 1.399 to 7.349 
Log-rank (Mantel Cox) Test Chi square: 7.578; P value: 0.0059 
Gehan-Breslow-Wilcoxon Test Chi square: 11.10; P value: 0.0009 
 
Median Survival GSI+cisplatin 19.50; GSI+MK-0646 26.00 
Ratio 0.7500 
95% CI of ratio 0.2400 to 1.260 
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Hazard Ratio Ratio: 1.042 
95% CI of ratio 0.4958 to 2.190 
Log-rank (Mantel Cox) Test Chi square: 0.01183; P value: 0.9134 
Gehan-Breslow-Wilcoxon Test Chi square: 2.275; P value: 0.1315 
 
Median Survival C 9.000; erlotinib 16.00 
Ratio 0.5625 
95% CI of ratio 0.06241 to 1.063 
Hazard Ratio Ratio: 4.015 
95% CI of ratio 1.684 to 9.571 
Log-rank (Mantel Cox) Test Chi square: 9.832; P value: 0.0017 
Gehan-Breslow-Wilcoxon Test Chi square: 12.03; P value: 0.0005 
 
Median Survival C 9.000; MK-0646 25.50 
Ratio 0.3529 
95% CI of ratio -0.1472 to 0.8530 
Hazard Ratio Ratio: 28.79 
95% CI of ratio 9.435 to 87.86 
Log-rank (Mantel Cox) Test Chi square: 34.84; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 28.61; P value: <0.0001 
 
Median Survival C 9.000; MK-0646+erlotinib 15.00 
Ratio 0.6000 
95% CI of ratio 0.09991 to 1.100 
Hazard Ratio Ratio:3.923 
95% CI of ratio 1.642 to 9.374 
Log-rank (Mantel Cox) Test Chi square: 9.460; P value: 0.0021 
Gehan-Breslow-Wilcoxon Test Chi square: 12.42; P value: 0.0004 
 
Median Survival C 9.000; MK-0646 then erlotinib 36.50 
Ratio 0.2466 
95% CI of ratio -0.2535 to 0.7467 
Hazard Ratio Ratio: 34.03 
95% CI of ratio 10.92 to 106.0 
Log-rank (Mantel Cox) Test Chi square: 37.02; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 29.91; P value: <0.0001 
 
Median Survival erlotinib 16.00; MK-0646 25.50 
Ratio 0.6275 
95% CI of ratio 0.1274 to 1.128 
Hazard Ratio Ratio: 7.872 
95% CI of ratio 3.067 to 20.20 
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Log-rank (Mantel Cox) Test Chi square: 18.41; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 17.46; P value: <0.0001 
 
Median Survival erlotinib 16.00; MK-0646+erlotinib 15.00 
Ratio 1.067 
95% CI of ratio 0.5666 to 1.567 
Hazard Ratio Ratio: 0.7894 
95% CI of ratio 0.3747 to 1.663 
Log-rank (Mantel Cox) Test Chi square: 0.3868; P value: 0.5340 
Gehan-Breslow-Wilcoxon Test Chi square: 0.1714; P value: 0.6788 
 
Median Survival erlotinib 16.00; MK-0646 then erlotinib 36.50 
Ratio Ratio 0.4384 
95% CI of ratio -0.06174 to 0.9384 
Hazard Ratio Ratio: 29.54 
95% CI of ratio 9.856 to 88.56 
Log-rank (Mantel Cox) Test Chi square: 36.54; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 30.02; P value: <0.0001 
 
Median Survival MK-0646 25.50; MK-0646+erlotonib 15.00 
Ratio 1.700 
95% CI of ratio 1.200 to 2.200 
Hazard Ratio Ratio: 0.07699 
95% CI of ratio 0.02814 to 0.2106 
Log-rank (Mantel Cox) Test Chi square: 24.93; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 22.53; P value: <0.0001 
 
Median Survival MK-0646 25.50; MK-0646 then erlotinib 36.50 
Ratio 0.6986 
95% CI of ratio 0.1985 to 1.199 
Hazard Ratio Ratio: 2.524 
95% CI of ratio 1.090 to 5.842 
Log-rank (Mantel Cox) Test Chi square: 4.672; P value: 0.0307 
Gehan-Breslow-Wilcoxon Test Chi square: 5.882; P value: 0.0153 
 
Median Survival MK-0646+erlotinib 15.00;MK-0646 then erlotinib 36.50 
Ratio 0.4110 
95% CI of ratio -0.08913 to 0.9111 
Hazard Ratio Ratio: 30.71 
95% CI of ratio 10.11 to 93.28 
Log-rank (Mantel Cox) Test Chi square: 36.49; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 29.84; P value: <0.0001 
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H1437 
Median Survival C 8.000; cisplatin 21.00 
Ratio 0.3810 
95% CI of ratio -0.1134 to 0.8753 
Hazard Ratio Ratio: 39.06 
95% CI of ratio 11.63 to 131.2 
Log-rank (Mantel Cox) Test Chi square: 35.17; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 29.23; P value: <0.0001 
 
Median Survival C 8.000; GSI 30.00 
Ratio 0.2667 
95% CI of ratio -0.2277 to 0.7611 
Hazard Ratio Ratio: 33.11 
95% CI of ratio 10.06 to 109.0 
Log-rank (Mantel Cox) Test Chi square: 33.17; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 28.37; P value: <0.0001 
 
Median Survival C 8.000; GSI+cisplatin 38.00 
Ratio 0.5526 
95% CI of ratio 0.05254 to 1.053 
Hazard Ratio Ratio: 20.12 
95% CI of ratio 6.801 to 59.50 
Log-rank (Mantel Cox) Test Chi square: 29.43; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 25.73; P value: <0.0001 
 
Median Survival C 8.000; GSI+MK-0646 42.00 
Ratio 0.1905 
95% CI of ratio -0.3039 to 0.6849 
Hazard Ratio Ratio: 39.06 
95% CI of ratio 11.63 to 131.2 
Log-rank (Mantel Cox) Test Chi square: 35.17; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 35.17; P value: <0.0001 
 
Median Survival cisplatin 21.00; GSI 30.00 
Ratio 0.700 
95% CI of ratio 0.1999 to 1.200 
Hazard Ratio Ratio: 3.020 
95% CI of ratio 1.2610 to 7.241 
Log-rank (Mantel Cox) Test Chi square: 6.138; P value: 0.0132 
Gehan-Breslow-Wilcoxon Test Chi square: 3.325; P value: 0.0682 
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Median Survival cisplatin 21.00; GSI+cisplatin 38.00 
Ratio 0.5526 
95% CI of ratio 0.05254 to 1.053 
Hazard Ratio Ratio: 20.12 
95% CI of ratio 6.801 to 59.50 
Log-rank (Mantel Cox) Test Chi square: 29.43; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 25.73; P value: <0.0001 
 
Median Survival cisplatin 21.00; GSI+MK-0646 42.00 
Ratio 0.5000 
95% CI of ratio -9.128e-005 to 1.000 
Hazard Ratio Ratio: 16.03 
95% CI of ratio 5.558 to 46.25 
Log-rank (Mantel Cox) Test Chi square: 26.35; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 24.04; P value: <0.0001 
 
Median Survival GSI 30.00; GSI+cisplatin 38.00 
Ratio 0.7895 
95% CI of ratio 0.2894 to 1.290 
Hazard Ratio Ratio: 3.089 
95% CI of ratio 1.349 to 7.074 
Log-rank (Mantel Cox) Test Chi square: 7.121; P value: 0.0076 
Gehan-Breslow-Wilcoxon Test Chi square: 7.790; P value: 0.0053 
 
Median Survival GSI 30.00; GSI+MK-0646 42.00 
Ratio 0.7143 
95% CI of ratio 0.2142 to 1.214 
Hazard Ratio Ratio: 4.534 
95% CI of ratio 1.882 to 10.93 
Log-rank (Mantel Cox) Test Chi square: 11.35; P value: 0.0008 
Gehan-Breslow-Wilcoxon Test Chi square: 9.153; P value: 0.0025 
 
Median Survival GSI+cisplatin 38.00; GSI+MK-0646 42.00 
Ratio 0.9048 
95% CI of ratio 0.4047 to 1.405 
Hazard Ratio Ratio: 1.105 
95% CI of ratio 0.5179 to 2.357 
Log-rank (Mantel Cox) Test Chi square: 0.06641; P value: 0.7966 
Gehan-Breslow-Wilcoxon Test Chi square: 0.08055; P value: 0.7765 
 
Median Survival C 8.000; erlotinib 19.00 
Ratio 0.4211 
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95% CI of ratio -0.07904 to 0.9211 
Hazard Ratio Ratio: 34.11 
95% CI of ratio 10.71 to 108.7 
Log-rank (Mantel Cox) Test Chi square: 35.65; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 29.53; P value: <0.0001 
 
Median Survival C 8.000; MK-0646 26.00 
Ratio 0.3077 
95% CI of ratio -0.1867 to 0.8021 
Hazard Ratio Ratio: 30.97 
95% CI of ratio 9.752 to 98.34 
Log-rank (Mantel Cox) Test Chi square: 33.91; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 27.90; P value: <0.0001 
 
Median Survival C 8.000; MK-0646+erlotinib 18.50 
Ratio 0.4324 
95% CI of ratio -0.06766 to 0.9325 
Hazard Ratio Ratio: 34.11 
95% CI of ratio 10.71 to 108.7 
Log-rank (Mantel Cox) Test Chi square: 35.65; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 29.53; P value: <0.0001 
 
Median Survival C 8.000; MK-0646 then erlotinib 35.00 
Ratio 0.2286 
95% CI of ratio -0.2658 to 0.7230 
Hazard Ratio Ratio: 30.97 
95% CI of ratio 9.752 to 98.34 
Log-rank (Mantel Cox) Test Chi square: 33.91; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 27.90; P value: <0.0001 
 
Median Survival erlotinib 19.00; MK-0646 26.00 
Ratio 0.7308 
95% CI of ratio 0.2364 to 1.225 
Hazard Ratio Ratio: 1.391 
95% CI of ratio 0.5550 to 3.488 
Log-rank (Mantel Cox) Test Chi square: 0.4959; P value: 0.4813 
Gehan-Breslow-Wilcoxon Test Chi square: 0.1642; P value: 0.2001 
 
Median Survival erlotinib 19.00; MK-0646+erlotinib 18.50 
Ratio 1.027 
95% CI of ratio 0.5269 to 1.527 
Hazard Ratio Ratio: 0.6593 
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95% CI of ratio 0.2847 to 1.526 
Log-rank (Mantel Cox) Test Chi square: 0.9459; P value: 0.3308 
Gehan-Breslow-Wilcoxon Test Chi square: 1.399; P value: 0.2368 
 
Median Survival erlotinib 19.00; MK-0646 then erlotinib 35.00 
Ratio 0.5429 
95% CI of ratio 0.04846 to 1.037 
Hazard Ratio Ratio: 7.671 
95% CI of ratio 2.796 to 21.04 
Log-rank (Mantel Cox) Test Chi square: 15.66; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 17.38; P value: <0.0001 
 
Median Survival MK-0646 26.00; MK-0646+erlotonib 18.50 
Ratio 1.405 
95% CI of ratio 0.9110 to 1.900 
Hazard Ratio Ratio: 0.6077 
95% CI of ratio 0.2677 to 1.380 
Log-rank (Mantel Cox) Test Chi square: 1.418; P value: 0.2338 
Gehan-Breslow-Wilcoxon Test Chi square: 2.960; P value: 0.0854 
 
Median Survival MK-0646 26.00; MK-0646 then erlotinib 35.00 
Ratio 0.7429 
95% CI of ratio 0.2540 to 1.232 
Hazard Ratio Ratio: 3.953 
95% CI of ratio 1.604 to 9.744 
Log-rank (Mantel Cox) Test Chi square: 8.920; P value: 0.0028 
Gehan-Breslow-Wilcoxon Test Chi square: 8.198; P value: 0.0042 
 
Median Survival MK-0646+erlotinib 18.50;MK-0646 then erlotinib 35.50 
Ratio 0.5286 
95% CI of ratio 0.03418 to 1.023 
Hazard Ratio Ratio: 7.882 
95% CI of ratio 2.974 to 20.89 
Log-rank (Mantel Cox) Test Chi square: 17.24; P value: <0.0001 
Gehan-Breslow-Wilcoxon Test Chi square: 18.47; P value: <0.0001 
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GSI treatment resulted in the effective killing of tumors in hypoxic areas 
Our previous findings suggested that Notch-1 promotes tumor cell survival under 
hypoxia, and targeting Notch-1 signaling using either siRNA against Notch-1 or GSI 
specifically kills NSCLC cells under hypoxia in vitro. Here, we wanted to further 
understand whether GSI treatment indeed targets hypoxic tumor cells in the tumor-
bearing mice. To answer this question, we excised the whole inferior right lung lobes of 
mice after treatment at their endpoints with GSI or vehicle control, and performed RNA 
isolation and quantitative RT-PCR (qRT-PCR) experiments using human-specific 
primers. The results showed that the expression levels of Notch targets HEY-L and HEY-
1 were significantly decreased in GSI treated mice compared to controls. Furthermore, 
the expression levels of two critical hypoxic markers glucose transporter 1 (GLUT-1) and 
vascular endothelial growth factor A (VEGF-A) were also greatly reduced in GSI treated 
mice lungs, suggesting a reduction in hypoxic regions upon GSI treatment. We also 
found decreased expression of IGF-1R, which confirmed our in vitro finding that Notch-1 
activates IGF-1R expression in hypoxic conditions (Figure 4.9). To specifically visualize 
the cell death in hypoxic tumor regions, we performed TUNEL staining analysis on 
frozen lung sections obtained from GSI and vehicle treated mice lungs. The results from 
TUNEL staining showed that GSI treatment promoted apoptosis in hypoxic tumor 
regions, whereas control mice did not show TUNEL signals in hypoxic tumor areas 
(Figure 4.10a-d). Consistently with the TUNEL results, we also detected cleaved 
(activated) caspase-3 in GSI treated mice lungs by GSI treatment (Figure 4.10e). All of 
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the above results suggest that GSI treatment caused specific apoptosis of hypoxic tumor 
cells.  
 
 
 
 
Figure 4.9 GSI treatment caused significant reduction in the expression of Notch 
target genes, hypoxic markers and IGF-1R. Quantitative RT-PCR analysis of the 
indicated mRNAs in control and GSI (MRK-003) treated mice lungs. Total RNA was 
isolated from the whole inferior right lung lobe of mice after euthanasia, reverse 
transcribed, and measured by qPCR using human-specific primers. The expression levels 
of indicated mRNAs were normalized with human ribosomal protein RPL13A. Columns 
represent averages, while bars represent standard deviation. The experiment was 
performed on 4 control and 4 GSI (MRK-003) treated mice. 
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Figure 4.10 GSI treatment led to apoptosis of hypoxic NSCLC cells. 
Immunofluorescent staining of hypoxic marker GLUT-1 (green) and in situ TUNEL 
assay (red) in a control mouse (b) and in a mouse treated with GSI (MRK-003) (d). (a) 
and (c) are the same regions of (b) and (d) in bright field, respectively. 8 µm thick section 
slides of frozen lungs were first immunolabeled with a mouse monoclonal antibody of 
GLUT-1, followed by incubation with a goat anti-mouse IgG conjugated with Alexa 
Fluor 488 (green). Subsequently, the slides were subjected to the reaction mixture for 
TUNEL labeling containing terminal deoxynucleotidyl transferase and TMR red dUTP, 
  
83 
washed and mounted following the protocol provided by the TUNEL kit manufacturer. 
Original magnification: 200 X. Cells in (d) appear larger compared to (b). We propose 
that this effect could be an artifact due either to cell death or other reasons. (e) Western 
blot analysis performed on 100 µg of total lung lysate extracted from two control mice 
(GSI -) and two mice treated with MRK-003 (GSI +). 
 
 
 
GSI treatment reduced brain and liver metastasis  
It has been shown that Notch signaling promotes tumor migration and invasion in 
hypoxia. Using species-specific GAPDH primers, we measured the ratio of human versus 
mouse cells in total DNA extracted from the whole right brain and left liver lobe. Our 
results agree with the previous findings: brain and liver metastasis were indeed reduced 
after GSI treatment (Figure 4.11). Note that all mice were sacrificed at their endpoint and 
still the tumor burden in the brain and liver of GSI treated mice were less than the 
controls although the GSI treated mice lived much longer than the control mice.  
 
 
 
 
Figure 4.11 GSI treatment caused significant reduction in brain and liver 
metastasis. Quantitative PCR (qPCR) analysis of the ratio of human versus mouse cells 
in DNAs extracted from brain and liver of control mice or GSI (MRK-003) treated mice 
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at the endpoint. This ratio was calculated by qPCR using primers specific for human or 
mouse GAPDH (this qPCR assay has been previously validated using known amount of 
cells). In the brain experiment, columns represent the average of 6 mice (controls: days at 
euthanasia 12.67 ± 4.18; GSI treated mice: days at euthanasia 17.83 ± 8.86). In the liver 
experiment we analyzed 6 control mice (days at euthanasia: 12.6 ± 4.22) and 7 GSI 
treated mice (days at euthanasia: 18.67 ± 7.84). Bars represent standard deviation.  
 
 
 
GSI treatment decreased the expression of glycolytic enzymes  
Recently, activation of Notch signaling has been shown to promote glycolysis 
through activating PI3K/Akt signaling. We measured the expression of glycolytic 
enzymes by quantitative RT-PCR. We consistently found that GSI treatment decreased 
the expression of glycolytic enzymes, such as hexokinase-2 (HK-2), pyruvate 
dehydrogenase kinase-2 (PDK-2), and aldolase-A (ALDOA) (Figure 4.12), suggesting 
glycolysis was inhibited upon GSI treatment.  
 
 
 
 
Figure 4.12 GSI treatment decreased the expression of glycolytic enzymes. 
Quantitative RT-PCR of hexokinase-2 (HK-2), pyruvate dehydrogenase kinase-2 (PDK-
2), and aldolase-A (ALDOA) mRNA in control (C) or GSI (MRK-003) treated mice 
lungs. Columns represent the average of 4 mice. Bars represent standard deviation. P 
values are indicated. 
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AIM2: DELINEATE THE DETAILED MECHANISM BY WHICH TUMOR 
EVASION OCCURRED DURING IGF-1R INHIBITORY ANTIBODY 
TREATMENT  
 
MK-0646 promoted IGF-1R degradation in a proteasome dependent manner 
To identify the mechanism by which MK-0646 inhibits the IGF-1R signaling 
pathway, we performed in vitro experiments on NSCLC cells exposed to MK-0646 for 
different amounts of time. We found that MK-0646 treatment of control cells caused 
rapid loss of IGF-1R protein and effective loss of Akt-1 activation by IGF-1 
administration to serum-starved cells. The transient ERK activation (measured by 
phosphorylated ERK1/2) within 1hr of IGF-1 stimulation was also lost in MK-0646 
treated cells (Figure 4.13a). More importantly, we found that MK-0646 reduced IGF-1R 
protein levels within 1hr of exposure to MK-0646. This effect was mediated by the 
proteasome degradation pathway, because the MK-0646 mediated IGF-1R degradation 
was blocked in the presence of a proteasome inhibitor (MG-132), but not a lysosome 
inhibitor (NH4Cl) (Figure 4.13b).  
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Figure 4.13 MK-0646 promoted IGF-1R degradation in a proteasome dependent 
manner. (a) Western blot analysis of H1437 cells treated with or without purified IGF-1 
(50ng/ml) or MK-0646 (2.5µg/ml). Cells were serum starved for 1 hour, and then 
exposed to IGF-1 treatment at the indicated time points. Note that IGF-1R was lost in the 
MK-0646 treated cells, and that IGF-1 activated Akt and ERK signaling were also 
inhibited. (b) Western blot analysis of H1437 cells treated with MK-0646 plus vehicle, or 
MK-0646 plus MG-132 (10µM) or NH4Cl (10mM) for the indicated times. 
 
 
 
Tumor evasion occurred after IGF-1R inhibitory antibody (MK-0646) treatment 
 Our preliminary data suggested that MK-0646 had a tumoristatic effect on 
NSCLC cells at the beginning of treatment. However, after the first two weeks, tumor 
cells resumed growth and ultimately led to the death of the experimental animals (Figure 
4.14). The recurrent malignancy and eventual fatality are commonly seen in anti-cancer 
therapy in humans (with the exception of some hormone-driven malignancies). 
Regardless of the therapeutic approach, tumors become resistant to adjuvant 
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radio/chemotherapy and eventually lead to the death of the patients. In this aim, we want 
to uncover the mechanism(s) that allow cancer cells to evade the deprivation of IGF-1R 
signaling.  
 
 
 
 
Figure 4.14.  Bioluminescence quantification of the tumor burden in the lungs of 
mice treated with IGF1-R inhibitory antibody (MK-0646). The Graphic shows the 
units of light recorded by an IVIS 100 at the indicated time points. Sixteen mice were 
injected with 0.25 mg of luciferin and imaged for 5 minutes. 
 
 
 
Phosphorylated EGF-R (pEGF-R) and EGF-R total protein levels were increased 
upon MK-0646 treatment in vivo and in vitro 
A recent study suggested that inhibition of Akt-1 signaling led to a compensatory 
activation of several receptor tyrosine kinases (RTKs), including EGF-R (Chandarlapaty 
et al., 2011). Since MK-0646 caused rapid loss of IGF-1R total protein and dramatic loss 
of Akt activation (Figure 4.13a), we wanted to investigate if tumor cells evaded the effect 
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of MK-0646 treatment through activating alternative RTKs. Proteomic RTK array 
analysis showed that the level of phosphorylated EGF-R (pEGF-R) was increased in the 
mouse lungs treated with IGF1-R inhibitory antibody (MK-0646) compared with controls 
(Figure 4.15). As activation of EGF-R signaling pathways can lead to cell survival and 
proliferation, this is a potential mechanism underlying the tumor survival when IGF-1R 
signaling is impaired. 
In order to delineate the detailed mechanism(s) by which EGF-R signaling is 
activated when IGF1-R signaling is impaired, we wanted to determine if we could 
achieve the same effect by inhibiting IGF1-R signaling in vitro. Briefly, we cultured 
NSCLC cells in the tissue culture media containing MK-0646 for three weeks, and 
detected increased phosphorylated EGF-R (pEGF-R), as well as total protein level of 
EGF-R. The similar results were obtained in tumors of mice treated with MK-0646 in 
vivo and in cells re-derived after necroscopy from lung tumors of mice treated with MK-
0646 (Figure 4.16c). This appeared to be a cell-autonomous phenomenon since A549 and 
H1437 cells treated for three weeks with MK-0646 in vitro also showed increased levels 
of pEGF-R and total EGF-R (Figure 4.16a, c). However, the increased total EGF-R 
protein was not due to increased mRNA expression (which indeed was reduced) (Figure 
4.16b). 
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Figure 4.15. Phosphorylated EGF-R (pEGF-R) was increased in IGF-1R inhibitory 
antibody (MK-0646) treated mouse lung compared to control. Representative human 
phospho-RTK array analysis of total protein lysates (250µg) obtained from control and 
IGF-1R inhibitory antibody treated mouse lungs at their endpoints. We performed a total 
of 4 assays and always detected a dramatic increase in EGF-R phosphorylation. In this 
particular example we also detected that ErbB3 and FGF-R3 increased phosphorylation 
upon MK-0646 treatment, but the only constant outcome that we identified was EGF-R 
hyperactivation. (b) Histogram quantification of selected phosphorylated proteins by 
measuring the mean spot pixel density from the arrays using image software analysis. 
Data were collected from 4 independent array experiments. White columns represent 
protein levels in lysates obtained from irrelevant IgG treated mice; black columns 
represent protein levels in lysates obtained from MK-0646 treated mice. Bars represent 
standard deviation. Note that only the increase in phosphorylated EGF-R of the MK-0646 
treated mouse lung was statistically significant. 
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Figure 4.16 MK-0646 treatment increased total EGF-R protein and phosphorylated 
EGF-R (pEGF-R) levels both in vitro and in vivo. (a) Western blot analysis of the 
indicated proteins in 2 representative protein lysates obtained from the postcaval lung 
lobe of a control mouse and MK-0646 treated mouse in 3 pooled cell lines re-derive after 
necroscopy from lung tumors of control mice and mice treated with MK-0646, in A549 
and H1437 cells treated either with an irrelevant human IgG or with MK-0646 for 3 
weeks. (b) qRT-PCR of the EGF-R mRNA measured from the sources specified in (a). 
Columns represent the average of 4 independent experiments; bars represent standard 
deviation. (C) Immunoprecipitation of the EGF-R from the sources specified in (a) 
followed by immunoblot analysis using the specified antibodies. IgG lanes: 
immunoprecipitation performed using a pre-immune mouse IgG (negative control). 
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Polyubiquitinated EGF-R was reduced and EGF-R protein accumulated in the 
plasma membrane upon MK-0646 treatment 
Since NSCLC cells treated with MK-0646 showed significant induction in EGF-R 
protein and pEGF-R levels in a transcription independent manner, we wanted to 
understand where the EGF-R protein accumulated in the cells and whether the EGF-R 
endocytosis/degradation pathway was affected by the treatment. We biotinylated the cell 
surface protein and performed a streptavidin pull down experiment to separate the 
membrane bound EGF-R from cytosolic EGF-R. We then determined the levels of 
phosphorylated EGF-R and total EGF-R protein by immunoprecipitating EGF-R and 
blotted for phosphorylated tyrosine. From the results of this experiment, we found that 
pEGF-R was increased in both the plasma membrane and cytosolic portion, while the 
total EGF-R protein was only accumulated on the cell plasma membrane (Figure 4.17a). 
Consistent with this result, our experiment on ubiquitinated EGF-R showed that there 
was reduced EGF-R polyubiquitination after MK-0646 treatment (Figure 4.17b), 
suggesting an altered EGF-R degradation pathway. The fact that total EGF-R protein 
accumulated on the plasma membrane also suggested that the EGF-R recycling process 
might be affected by long term MK-0646 treatment.  
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Figure 4.17 MK-0646 treated NSCLC cells showed increased pEGF-R in the plasma 
membrane and cytosol, increased EGF-R total protein only in the plasma 
membrane, and reduced EGF-R polyubiquitination. (a) Biotinylation of cell-surface 
proteins; streptavidin pull-down followed by EGF-R immunoprecipitation (see Materials 
and Methods for details) and Western blot analysis performed using anti-phosphorylated 
tyrosine and anti-EGF-R antibodies. IgG lanes: EGF-R immunoprecipitation performed 
using a pre-immune mouse IgG (negative control) (b) EGF-R immunoprecipitation 
followed by Western blot analysis in A549 and H1437 cells treated with MK-0646 in 
vitro for three weeks, using antibodies against ubiquitin and EGF-R. IgG lanes: same as 
in (a). 
 
 
 
MK-0646 treatment increased the expression of EGF-R ligand amphiregulin by 
activating Akt-1 signaling 
We also found that the IGF-1R inhibitory antibody (MK-0646) treatment led to 
Akt-1 activation, both in cells re-derived from MK-0646 treated mice lungs and in cells 
treated with MK-0646 for three weeks in vitro (Figure 4.18a). Since we were able to 
detect an increased level of pEGF-R in cells treated with MK-0646 in vitro for three 
weeks, this EGF-R activation effect appeared to be a cell-autonomous phenomenon. 
Therefore, we performed qRT-PCR analysis to access the expression levels of all known 
EGF-R ligands (including EGF, TGFα, HBEGF, betacellulin, epiregulin, amphiregulin 
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and epigen) in MK-0646 treated cells compared to controls treated with an irrelevant IgG. 
We found that only the mRNA of amphiregulin was elevated in tumors obtained from 
mice lungs, as well as in cell lines re-derived from tumors and in cells treated with MK-
0646 in vitro (Figure 4.18b).  
In order to verify whether the increased amphiregulin mRNA was dependent on 
Akt-1 activation, A549 and H1437 cells were treated with either IGF-1 (50 ng/ml) or Akt 
pan-inhibitor (MK-2206) (1 µM). Cells treated with IGF-1 showed significantly 
increased mRNA levels of amphiregulin, whereas Akt pan-inhibitor treated cells 
displayed reduced mRNA levels of amphiregulin in comparison to controls (Figure 
14.19a).  Transfecting cells with plasmid encoding a constitutively active Akt-1, or a 
dominant-negative Akt-1 (Figure 14.19b) further confirmed that the expression level of 
amphiregulin is regulated by Akt signaling. Taken together, the results in Figure 4.18 and 
Figure 4.19 suggested that MK-0646 treatment increased the expression level of EGF-R 
ligand amphiregulin by activating Akt-1 signaling. Since it has been shown that 
amphiregulin targets EGF-R for membrane recycling rather than lysosomal degradation 
(Stern et al., 2008), these results also provided a possible explanation for the increased 
EGF-R protein on the plasma membrane shown in Figure 4.17.  
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Figure 4.18 MK-0646 treatment led to Akt activation and increased ampheregulin 
expression. (a) Western blot analysis of phosphorylated Akt (pAkt) on Ser 473 and total 
Akt proteins in 3 pooled cell lines re-derived after necroscopy from lung tumors of 
control mice and mice treated with MK-0646, in A549 cells treated either with an 
irrelevant human IgG or with MK-0646 for 3 weeks.  (b) qRT-PCR experiment of 
amphiregulin mRNAs in RNA samples extracted from the postcaval lung lobe of a 
control mouse and a MK-0646 treated mouse, in 3 pooled cell lines re-derived after 
necroscopy from lung tumors of control mice and mice treated with MK-0646, in A549 
and H1437 cells treated either with an irrelevant human IgG or with MK-0646 for 3 
weeks. 
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Figure 4.19 The expression level of amphiregulin is regulated by Akt signaling. (a) 
NSCLC cell lines A549 and H1437 were treated either with vehicle (C), with 50 ng/ml of 
IGF-1, or with 1 µM of MK-2206. Left, representative Western blot analysis using 
antibodies against phosphorylated Akt (pAkt) (Ser473), total Akt and GAPDH; right, 
qRT-PCR of the amphiregulin mRNA. Columns represent the average of 4 independent 
experiments; bars represent standard deviation. (b) A549 and H1437 cells were 
transfected either with a control plasmid (C), with a plasmid expressing constitutively 
active Akt-1 (Myr-Akt), or with a plasmid expressing dominant negative Akt-1 (DN-
Akt). Left, representative Western blot analysis using the same antibodies described in 
(a); right, qRT-PCR of the amphiregulin mRNA. Columns represent the average of 4 
independent experiments; bars represent standard deviation. 
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AIM3: STUDY IF ADMINISTRATION OF IGF-1R INHIBITORY ANTIBODY 
SENSITIZES NSCLC CELLS TO EGF-R INHIBITION 
 
MK-0646 treated NSCLC cells became sensitive to EGF-R inhibiton in vitro  
Since NSCLC cells treated with MK-0646 overactivated EGF-R both in vivo and 
in vitro, we questioned whether such cells could have become more sensitive to the EGF-
R inhibitor erlotinib. To assess this hypothesis, three cell lines (A549, H226, and H1437) 
were treated with MK-0646 for three weeks in vitro (control cells were exposed to an 
irrelevant human IgG). Control and MK-0646 treated cells were then exposed to 5 µM 
erlotinib. We measured Br-dU incorporation (an example is provided in Figure 4.20a), 
and growth curves were assessed using MTT assays (Figure 4.20b). In all cases, cells 
pretreated with MK-0646 displayed the highest sensitivity to erlotinib. We further 
confirmed these results using a lentiviral vector expressing shEGF-R to stably knock 
down EGF-R in cells pre-treated with MK-0646 (Figure 4.21). The results also indicated 
that NSCLC cells became sensitive to EGF-R downregulation after MK-0646 treatment. 
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Figure 4.20 NSCLC cells pre-treated with MK-0646 became sensitive to EGF-R 
inhibitor (erlotinib). (a) Representative 5-bromo-2'-deoxyuridine (Br-dU) 
incorporation/7AAD staining assay followed by FACS analysis of A549 cells exposed 
either to a pre-immune human IgG (C) or to MK-0646 for 3 weeks (MK-0646). From left 
to right: control cells, control cells exposed to 5 µM erlotinib, MK-0646 treated cells 
exposed to 5 µM erlotinib for 48 hours. (b) NSCLC cell lines A549, H226 and H1437 
were exposed either to a pre-immune IgG (C) or to MK-0646 for 3 weeks (MK-0646). 
Cells were then treated with vehicle or 5 µM erlotinib and MTT assays were performed at 
the indicated time points (24hr, 48hr and 72hr). Curves summarize 3 independent 
experiments. Bars represent standard deviation. 
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Figure 4.21 NSCLC cells pre-treated with MK-0646 became sensitive to EGF-R 
downregulation. (a) MTT assay performed with NSCLC cells A549 and H1437 pre-
treted with and without MK-0646 stably transduced with either vector or lentivirus 
expression shEGF-R at indicated timepoints (24 hr, 48 hr and 72 hr). (b) Western blot 
analysis of A549 and H1437 cells transduced with vector or lentivirus expressing shEGF-
R using antibodies against EGF-R and GAPDH. 
 
 
 
Administration of MK-0646 followed by EGFR inhibitor (erlotinib) had improved 
efficacy in treating advanced NSCLC in vivo 
If the tumor evasion that occurred during MK-0646 treatment was due to 
activated EGF-R signaling, then administration of IGF-1R inhibitory antibody followed 
by an EGFR inhibitor should have better efficacy in treating advanced NSCLC. To test 
this hypothesis, we performed in vivo experiments by treating experimental animals with 
MK-0646 for three weeks (this is when tumors rebounded, see Figure 4.14), followed by 
erlotinib treatment (sequential therapy) in the same orthotopic mice models we have 
established. For comparison, we also included a combination therapeutic regimen in 
which the tumor-bearing mice were treated with MK-0646 together with erlotinib from 
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day one. The results confirmed that mice treated with MK-0646 for three weeks followed 
by erlotinib treatment significantly improved median survival compared to combination 
therapy using MK-0646 and erlotinib from the beginning of treatment or using single 
agent alone (Figure 4.8 right panel and Table 4.2).  
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CHAPTER 5 
DISCUSSION 
 Tumor hypoxia is commonly seen in many types of cancer. It has been linked 
with cancer recurrence, radio/chemotherapy resistance, and maintaining the survival and 
growth of the cancer stem cells population (Keith and Simon, 2007). Current anticancer 
therapies that combine chemo/radiotherapy with antiangiogenic agents have generally 
failed and led to tumor recurrence because they are unable to target the hypoxic tumor 
microenvironment (Milas and Hittelman, 2009). Previous work from our laboratory 
indicated that under hypoxic conditions, Notch-1 is activated and stabilized by hypoxia 
inducible factor-1α (HIF-1α). On one hand, activated Notch-1 increases the expression 
level of IGF-1R and, on the other hand, it decreases PTEN expression. Both of these 
events lead to Akt-1 activation, which provides survival signals to NSCLC cells (and 
possibly other solid tumors) specifically under hypoxic condition (Eliasz et al., 2010).  
In this dissertation, the detailed mechanism through which Notch-1 regulates the 
expression of IGF-1R has been studied. First, we tested the effect of Notch-1 downstream 
targets on IGF-1R regulation, including HES-1, HES-5, HEY-1, HEY-L and c-MYC. 
However, none of these genes were able to regulate IGF-1R expression. Therefore, we 
hypothesized that Notch-1 directly regulates IGF-1R expression through CBF-1. 
Chromatin immunoprecipitation experiment suggested that Notch-1 directly associated to 
the 5’ region of the IGF-1R first intron along with CBF-1 and the coactivators MAML-1 
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and p300. Additionally, transfection of the NSCLC cells with a plasmid encoding 
dominant-negative MAML-1 disrupted this association and dramatically reduced the 
amounts of acetylated histone H3 in that DNA region. It has been shown that 
transcriptional regulatory regions can be located in an intron or exon. For example, IGF-1 
expression was shown to be regulated by an E box in the exon 1 promoter region 
(McLellan et al., 2006). The transcriptional upregulation of IGF-1R by Notch-1 is 
consistent with previous findings that most tumor suppressors repress IGF-1R gene 
transcription, while oncogenes enhance the expression level of IGF-1R. For example, 
wild-type tumor suppressor p53 dramatically suppresses the IGF-1R promoter activity by 
interacting with the TATA box-binding protein, thus preventing the formation of the 
initiation complex at the IGF-1R promoter. However, mutant p53 stimulates the 
expression of IGF-1R and activates IGF-1R signaling (Werner et al., 1996). Similar to 
p53, expression of tumor suppressor breast cancer type 1 susceptibility protein (BRCA-1) 
also resulted in significant reduction in endogenous IGF-1R levels and IGF-1R promoter 
activity (Maor et al., 2000).  
We also found that Notch-1 is activated in hypoxic tumor regions, which leads to 
maximal IGF-1R expression and Akt-1 activation in a mouse model of advanced 
NSCLC. This in vivo finding further confirmed our previous in vitro results that Notch-1 
is activated under hypoxia to activate IGF-1R and Akt-1 signaling, since it has been 
shown that mTORC-1 activity is inhibited in the hypoxic tumor microenvironment 
(Vadysirisack and Ellisen, 2012), and that autophagy is promoted in these tumor areas 
(Noman et al., 2011; Vadysirisack and Ellisen, 2012). The fact that IGF-1R is maximally 
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expressed in hypoxic tumor regions could be due to the loss of a negative feedback loop 
mediated by mTORC-1 activity on the insulin receptor substrate 1 (IRS-1).  
We have gathered evidence suggesting that hypoxia activates Notch-1, which in 
turn leads to the increased expression of IGF-1R and activated Akt-1 signaling, and 
eventually survival of the hypoxic tumor cells. Additionally, Notch downstream signaling 
can also be triggered by IGF-1R signaling through increasing the level of HIF-1α 
(Laughner et al., 2001; Zhong et al., 2000; Zundel et al., 2000). Therefore, a positive 
feedback loop is formed between Notch-1 and IGF-1R signaling pathways. To better 
target the hypoxic tumor microenvironment and to improve the efficacy of current 
therapeutic regimens for NSCLC, the major aim in this dissertation is to target the Notch-
1/IGF-1R/Akt-1 pro-survival signaling pathway using specific inhibitors, alone or in 
combination, to interfere with the survival of hypoxic NSCLC cells. We injected NSCLC 
cell lines A549 and H1437 through the tail vein to generate the orthotopic mouse model 
rather than a subcutaneous xenograft mouse model, because the orthotopic model can 
better recapitulate the heterogeneous tumors of the lungs, which have a mix of hypoxic 
and well-oxygenated tumor regions. Moreover, tumor masses in the lungs are likely to 
produce cardiopulmonary syndrome, thus further reproducing conditions similar to what 
is clinically observed. We limited our experiments to two cell lines, because a number of 
other NSCLC cell lines we have tested, including H1299, H1650 and H838, did not yield 
an acceptable tumor take in the mice lungs. Injection of H1299 into mice eventually 
generated brain tumors and, 5-weeks after injection, H838 and H1650 did not show any 
tumor formation measured by luminescence from luciferase activity.  One possible 
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explanation for the unaccepted tumor intake is that the highly oxygenated environment of 
the lung interferes with the localization and growth of NSCLC tumor initiating cells, 
which requires hypoxic conditions (Conley et al., 2012; Gustafsson et al., 2005; Keith 
and Simon, 2007). We also decided to initiate the therapies when the tumor burden was 
extensive, because most of the patients diagnosed with NSCLC are at advanced stages 
(IIIB and mostly IV).  
Mice treated with GSI had a significantly prolonged median survival. Moreover, I 
have found that GSI treatment specifically depleted hypoxic tumor cells, which 
confirmed our previous finding that Notch-1 activation provided survival signals to 
NSCLC cells specifically in hypoxia (Chen et al., 2007; Eliasz et al., 2010). Most of the 
GSI treated experimental animals reached their endpoints due to a significant decrease in 
body weight. This could be explained by the disrupted intestine integrity due to 
inactivation of Notch signaling by GSI, since it has been shown that simultaneous 
inhibition of Notch-1 and Notch-2 in the intestine causes a significant loss in the number 
of intestinal crypt progenitor cells (Riccio et al., 2008; Wu et al., 2010).  However, in 
humans, parenteral supportive care may reduce this undesired side effect significantly, 
allowing for a more prolonged survival time. Recently, a number of fully humanized 
monoclonal therapeutic antibodies that target individual Notch receptors have been 
developed. They can specifically prevent the cleavage of Notch receptors and thereby, the 
activation of downstream Notch signaling.  However, it may not be beneficial to use 
these antibodies to target a hypoxic tumor microenvironment. Large molecules, such as 
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antibodies may not be able to reach the hypoxic tumor areas due to their distance from 
the functional vasculature.  
The quantitative PCR performed using human and mouse specific GAPDH 
primers showed that the brains and livers of the mice had a reduced ratio of human versus 
mouse cells in GSI treated mice. Notably, the GSI treated mice were sacrificed, and the 
brain and liver tissues were collected at a later time point since they survived much 
longer (15.5 and 30 days for A549 and H1437 injected mice, respectively) compared with 
control mice (9 and 8 days for A549 and H1437 injected mice, respectively). These 
results suggested that GSI treated mice could have reduced tumor metastasis to the brain 
and liver. Moreover, previous literature has also suggested that Notch signaling is critical 
in mediating hypoxia-induced tumor cell migration and invasion (Sahlgren et al., 2008). 
Since cisplatin, a current chemotherapeutic drug that kills highly proliferating cells, and 
GSI treatment specifically targets hypoxic tumor regions that are quiescent and therefore 
nonresponsive to chemotherapeutic agents, we hypothesized that combination therapy 
using these two agents may improve the efficacy of NSCLC treatment. Indeed, we found 
that combining GSI with cisplatin significantly improved the median survival of the mice 
compared to mice receiving a single agent alone, which also confirmed the previous 
finding that GSI can sensitize cancer cells to cisplatin exposure (Song et al., 2008).  
During the administration of pan Akt inhibitor MK-2206, we found that this drug 
caused severe glucose intolerance and very rapid weight loss. The treatment schedule and 
dosage were based on the result of a preliminary experiment, which suggested that the 
maximum tolerated dosage in SCID mice was 3 consecutive administrations of 80 mg/kg 
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per week.  This finding is in accordance with the phenotype of Akt-2 and Akt-3 double 
knockout mice, which are highly insulin and glucose intolerant and display a 25% 
reduction in body mass, and with the lethal phenotype of the Akt triple knockout 
(Dummler et al., 2006). However, She et al. (She et al., 2010) have used a similar 
compound alone (100 mg/kg for 5 consecutive days per week) and in combination with a 
MEK inhibitor in nude mice for more than 20 days, obtaining slower tumor growth of 
subcutaneous xenograft models. Hirai et al., who used MK-2206 at a dose of 120 mg/kg 
with our administration schedule, both alone and in combination with lapatinib or 
erlotinib in nude mice for more than 15 days, also attained slower tumor growth of 
subcutaneous xenograft models (Hirai et al., 2010). The discrepancy between our results 
and those obtained in the aforementioned studies could be explained by a higher 
susceptibility of NOD-SCID mice to Akt inhibition compared with nude mice or by 
differences in glucose consumption between a subcutaneous tumor model compared with 
multiple tumor masses in the lungs. 
IGF-1R inhibitory antibody (MK-0646) treatment significantly extended the 
survival of mice compared to the control treatment. Combinational therapy using GSI and 
MK-0646 significantly increased median survival compared to a single agent alone. 
Although the IGF-1R is maximally expressed in hypoxic tumor areas, treatment with this 
antibody did not appear to target the hypoxic tumor microenvironment specifically, 
probably due to the fact that an antibody has difficulty penetrating poorly vascularized 
tumor regions.  
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Three weeks after MK-0646 treatment, tumor burden started to rebound and 
eventually led to the death of the experimental animals. We identified that EGF-R is the 
most important player in mediating this treatment evasion process. Therefore, we 
hypothesized that sequential therapy with MK-0646 followed by erlotinib treatment may 
improve the efficacy of NSCLC treatment. Indeed, in our orthotopic model, mice treated 
with MK-0646 for three weeks followed by erlotinib treatment had a dramatically 
improved median survival compared to a single agent or combination therapy (MK-0646 
and erlotinib simultaneously started from day one of treatment). IGF-1R inhibitory 
antibodies have been implicated in anticancer therapies targeting different types of cancer. 
Phase I and II clinical trials with these antibodies were very promising, and suggested 
little toxicity, mainly of hyperglycemia and increased insulin levels. However, a recent 
phase III trial of figitumumab, another humanized monoclonal antibody against IGF-1R 
in NSCLC, did not improve overall survival in combination with carboplatin plus 
paclitaxel, suggesting a lack of efficacy. This might be due to increased resistance since 
we have found that tumor cells become resistant to IGF-1R inhibitory antibody 
treatments (MK-0646) owing to increased EGF-R activity. Therefore, the above evidence 
strongly indicates that the IGF-1R inhibitory antibody treatments should be used in 
combinational or sequential therapies to overcome the problem of tumor evasion 
occurring after IGF-1R deprivation. Here, for the first time, we provide evidence that 
MK-0646 could be used in a window of time during therapeutic intervention to 
sensitize NSCLC cells to erlotinib. This drug is used as a second line therapeutic in 
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NSCLC patients who have failed standard carboplatin plus paclitaxel and it extends 
median survival for about 3 months.  
To further study the detailed mechanism by which EGF-R is activated upon IGF-
1R deprivation, we cultured the NSCLC cells in the culture media containing MK-0646 
for three weeks in vitro and found EGF-R activation, similar to the results obtained from 
mice lung tumors in vivo. This observation highly suggested that the effect mediated by 
MK-0646 on EGF-R activation is a cell autonomous effect. We also found that MK-0646 
seems to increase the EGF-R expression and activation mainly through protein 
stabilization. Biotinylation experiments showed that MK-0646 treatment increased EGF-
R expression at the plasma membranes rather than in cytosolic fractions, suggesting rapid 
recycling of the receptor. Increased recycling and activation of EGF-R could be due to 
autocrine of amphiregulin. This EGF-R ligand has been shown to cause both fast and 
slow EGF-R recycling and does not target EGF-R to lysosomal degradation (Stern et al., 
2008).  Moreover, amphiregulin stimulation of wild-type EGF-R has been shown to 
sensitize NSCLC cells to EGF-R inhibitors, which are mostly effective in patients with 
EGF-R activating mutations (Yonesaka et al., 2008). Furthermore, 
immunohistochemistry studies suggested that NSCLC patients with high levels of 
amphiregulin expression and wild-type EGF-R respond better to EGF-R inhibitors 
(Chang et al., 2011).  Moreover, we have found that Akt-1 activation positively regulates 
the amphiregulin mRNA expression levels. Previous studies have placed Akt-1 
downstream of amphiregulin/ErbB signaling. It is possible that in NSCLC cells, a 
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positive feedback loop exists between the ligand and one or more of its downstream 
effectors (Dong et al., 2011; Yotsumoto et al., 2010).  
The in vitro experiments in which NSCLC cells were cultured in the presence of 
MK-0646 containing culture media showed increased EGF-R protein levels and 
activation after three weeks of treatment, whereas EGF-R levels remained unchanged 
after short-term treatment. (We have tested 24 hr, 48 hr and 72 hr, data not shown). One 
possible explanation for this phenomenon is that MK-0646 treatment may actively select 
pre-existing cells expressing a higher level of EGF-R. To better understand whether MK-
0646 treatment increases EGF-R protein levels through selecting pre-existing ‘EGF-R 
high’ (in terms of protein level) cell populations or, directly increases the expression of 
EGF-R, we performed FACS analysis of A549 cells for EGF-R surface expression levels, 
and sorted for ‘EGF-R high’ and ‘EGF-R low’ cells (Figure 5.1a). To understand if 
‘EGF-R high’ or ‘EGF-R’ low cells are able to maintain their phenotype after sorting, the 
cells were cultured for a week in the absence of MK-0646, and reanalyzed for EGF-R 
surface level by FACS. We found that the distribution of surface EGF-R in both ‘EGF-R 
high’ and ‘EGF-R low’ cells went back to the same as their parental cells, which were 
A549 cells before sorting (Figure 5.1b). This would suggest that ‘EGF-R high’ and 
‘EGF-R low’ A549 cells would not keep their phenotype for more than one week. 
However, these results could not answer the question of whether MK-0646 treatment 
actively selects pre-existing ‘EGF-R high’ cells or directly increases the protein level of 
EGF-R, because MK-0646 was constantly provided in the culture medium of NSCLC 
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cells when we performed the experiment with MK-0646 and found increased EGF-R 
protein level and activity. 
 
 
 
 
Figure 5.1 EGF-R surface expression remained the same one-week after sorting. (a) 
A549 cells were stained with antibody against EGF-R (NeoMarkers) and Alexa Flour 
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488. Cells expressing low surface level of EGF-R (GFP-DIM) and high surface level of 
EGF-R (GFP-BRIGHT) were FACS sorted. (b) One week after the sorting experiment 
indicated in (a), the sorted cells and A549 parental cells were surface stained with EGF-R 
antibody and Alexa Flour 488, or Alexa Flour 488 only (negative control). FACS 
analysis was performed on the stained cells.  
 
 
 
Taken together, we have found that the hypoxic tumor microenvironment could 
be targeted by administration of GSI. GSI treatment not only reduced tumor growth in 
hypoxic areas, but also significantly reduced tumor metastasis. Combining GSI and 
cisplatin had better efficacy in treating mice bearing advanced NSCLC. Therefore, GSI 
could be used in combination with other chemotherapeutic agents to target both hypoxic 
and highly proliferating cells. Moreover, we have also identified the mechanism that 
leads to tumor evasion from IGF-1R inhibition, which is by activating the EGF-R 
signaling pathway. MK-0646 treatment caused upregulation of amphiregulin, which in 
turn activates and stabilizes EGF-R. Furthermore, sequential therapy using MK-0646 
followed by erlotinib treatment dramatically improved the survival of experimental 
animals. This study has considerable clinical significance because IGF-1R inhibitory 
antibodies are under clinical trials and face the problem of lack of efficacy due to 
resistance. Our study suggests that targeting IGF-1R could be used in a window of time 
during therapeutic intervention to sensitize NSCLC cells to EGF-R inhibition.  
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